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Abstract 
Several mammalian arenaviruses can infect humans and non-human primates and can 
cause severe and deadly hemorrhagic fever diseases. There are currently no FDA-
approved vaccines available for the prevention of infection by any of these pathogenic 
arenaviruses and treatment options for the infections are extremely limited. Arenavirus is 
an enveloped, bi-segmented, single-stranded RNA virus. Its genome encodes four viral 
proteins: the RNA-dependent RNA polymerase L, the nucleoprotein NP, the glycoprotein 
complex GPC, and the matrix protein Z. Arenaviral GPC plays critical roles in the first 
step of virus infection (i.e, cell entry), which involves receptor recognition and virus-host 
membrane fusion activity. Arenaviral NP is a multifunctional protein, which is involved 
in the formation of the viral ribonucleoprotein (RNP) complex needed for viral genome 
replication and transcription, and in host immunosuppression. Arenaviral L protein, 
together with NP, is responsible for genome replication and transcription. Arenaviral Z 
protein is the driving force of virion budding from the membrane of the infected cells and 
is also involved in mediating immune suppression. My study focused on the roles of 
arenaviral GPC and NP in mediating cell entry and host immune suppression. Arenaviral 
GPC is synthesized as a single polypeptide and is post-translationally processed by the 
cellular signal peptidase and S1P cellular protease into stable signal peptide (SSP), the 
receptor-binding GP1 and transmembrane GP2 subunits. My thesis focused on 
characterizing (1) the role of the glycoprotein SSP in mediating entry of the Pichinde 
virus (PICV) into cells in culture and its role in disease pathogenesis in guinea pigs, (2) 
the role of several conserved amino acids residues in the glycoprotein GP2 C-terminal 
domain (CTD) of PICV in mediating virus entry in vitro, and (3) the role of NP in 
mediating immune suppression via the PACT-RIG-I innate immune pathway. 
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Chapter I 
Introduction 
Arenaviruses are ambisense RNA viruses that are divided into the Old World (OW) and 
New World (NW) virus groups based on their phylogenetic, serological, and 
geographical differences.  While the prototypic OW arenavirus LCMV with worldwide 
distribution causes only mild illness in immunocompetent individuals, two other known 
OW arenaviruses (LASV and LUJV, both found in Africa) can cause severe hemorrhagic 
fever (HF) in humans. In addition, several of the NW arenaviruses in South America 
(e.g., JUNV, MACV, SABV, GTOV, and CHPV) can also cause severe hemorrhagic 
fevers (HF).  There are currently limited preventative and therapeutic options for patients 
infected with these highly pathogenic viruses. Candid #1 is the only vaccine currently 
available against JUNV infection (1) but is only licensed for the endemic areas in 
Argentina. Ribavirin, a nucleoside analog, has been used for the treatment of arenavirus 
infections but it has had mixed success and significant toxicity (2). 
Besides the aforementioned pathogenic human arenaviruses, there are many other known 
and emerging arenaviruses that have no known causal roles in humans (3, 4), including 
but not necessarily limited to a new group of snake-borne arenaviruses in the 
Reptarenavirus genus of the Arenaviridae family(5) An important question is why some 
arenaviruses cause severe disease in humans, while others do not.  Recent studies using 
viral reverse genetics, cell-based assays, animal models, and human genome-wide 
association analyses have revealed several potential mechanisms of arenaviral 
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pathogenicity.  We will summarize current understanding of the roles of the different 
viral and cellular factors that contribute to the degrees of arenavirus virulence in humans. 
1. Human diseases caused by OW and NW arenaviruses 
LASV is responsible for up to 300,000 infections and 5,000-10,000 deaths annually in 
endemic areas of West Africa (2).  LASV infection, which is often misdiagnosed, can 
result in a wide range of disease symptoms ranging from non-symptomatic to multi-organ 
failure and death. Some general symptoms include fever, cough, sore throat, malaise, 
severe headache, nausea, vomiting, diarrhea, and can develop into petechial hemorrhage, 
facial swelling (edema) (6). More severe symptoms include pleural effusion, 
thrombocytopenia, leukopenia, sensorineural hearing loss that occurs in up to one-third of 
patients encephalopathy, seizures, coma, mucosal bleeding, pulmonary edema, 
respiratory distress, and shock that culminates in the death of the patients (6, 7).  The 
only other known hemorrhagic fever-causing OW arenavirus LUJV was identified during 
an outbreak of the disease in Lusaka (Zambia) and Johannesburg (Republic of South 
Africa) in 2008 (8). LUJV-infected patients experienced fever, diarrhea, vomiting, chest 
pain, sore throat, rash, myalgia, facial and/or cerebral edema, mild bleeding, respiratory 
distress, elevated liver transaminases, and thrombocytopenia (9).     
The OW LCMV virus is found worldwide because its natural host (mus muculus) has a 
wide distribution. While most acquired LCMV infections are either asymptomatic or mild 
(e.g., fever, sore throat, cough, headache, muscle aches, malaise, photophobia, nausea, 
vomiting, thrombocytopenia and leukopenia) (10, 11) , LCMV infections have also been 
shown to cause neurological symptoms, such as aseptic meningitis or 
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meningoencephalitis (10, 11). Patients with meningitis may experience fever, headache, 
myalgia, stiff neck, malaise, and nausea, while those with meningoencephalitis can 
present with more severe neurological symptoms such as confusion and motor-sensory 
abnormalities.  While acquired LCMV infection does not pose a serious threat to 
immune-competent adults, congenital infection with LCMV can be quite serious.  
Congenital LCMV infection can result in spontaneous abortion and fetal death, or leave 
infants with permanent visual and/or neurological impairments. While 35% of reported 
cases of congenital LCMV infection are fatal (12), we do not know the exact incidence of 
congenital LCMV infections since infants are not commonly tested for the infection and 
that only serious cases have been reported (13).  In recent years, LCMV has shown to be 
an important pathogen that can cause severe symptoms in solid organs transplanted 
recipients, including but not necessarily limited to encephalopathy, coagulopathy, 
thrombocytopenia, leukocytosis, and graft dysfunction.  Fourteen cases of LCMV 
infection in transplant recipients have so far been identified, eleven of which have proven 
fatal (14-16). Another OW arenavirus (Dandenong virus) was isolated from fatal organ-
transplant patients (9).    
Several South American NW arenaviruses (e.g., JUNV, MACV, GTOV, CHPV, and 
SABV) can cause HF with high rates of mortality in humans.  While only small numbers 
of human infections with SABV and CHPV are known (17, 18), many cases of human 
disease have been reported for JUNV, MACV or GTOV (19-25).  JUNV is the causative 
agent of Argentine hemorrhagic fever. JUNV-infected patients may show mild symptoms 
such as fever, myalgia, mild hypotension, conjunctivitis, petechial hemorrhage of the soft 
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tissues, lethargy, and irritability. However, in severe cases, patients can experience 
hemorrhagic fever, leukopenia, thrombocytopenia, shock and seizures (24). Other 
pathogenic NW arenaviruses (e.g., MACV, SABV, GTOV, and CHPV) can also cause a 
wide range of symptoms, ranging from fever, sore throat, headache, myalgia, nausea, 
abdominal pain, vomiting, diarrhea, mucosal and/or conjuntival petechia to more severe 
symptoms, such as thrombocytopenia, leukopenia, hematuria, tremors, pulmonary edema, 
respiratory distress, coma, shock, and hepatic and gastrointestinal hemorrhages and 
necrosis. While hepatitis is common in severe cases of Lassa fever, it is unusual or mild 
in South American hemorrhagic fevers.  Neurologic symptoms, hemorrhaging, 
leukopenia, and thrombocytopenia are more common in JUNV, GTOV, or MACV 
infections than LASV infections (26). 
2. Basic biology of arenaviruses 
2.1. Genome structure 
The arenavirus genome is composed of two single-stranded negative-sense RNAs of 
about 7.2 kb and 3.5 kb (Fig. 1). Each of genomic segments codes for two proteins from 
opposite orientation known as ambisense coding strategy. The large (L) segment encodes 
the RNA-dependent RNA polymerase (RdRp) L protein and matrix protein Z. The small 
(S) segment encodes the nucleoprotein (NP) and glycoprotein precursor (GP) (27). 
Arenavirus genomic RNA segments do not serve as the template for translation directly. 
Due to the ambisense coding strategy (Fig. 2), the NP and L mRNAs are transcribed from 
genomic RNAs, whereas the GP and Z viral mRNA are transcribed from the anti- 
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Fig. 1 
 
Fig. 1. Arenavirus genome structure: Arenaviruses are enveloped RNA viruses with a 
single-stranded ambisense genome that is composed of two segments. The genomic L 
(large) segment encodes the Z matrix protein and the L polymerase protein, and the S 
(small) segment encodes the glycoprotein (GP) and nucleoprotein (NP). The genes 
encoded on each segment are separated by noncoding intergenic regions (IGR). The 
linear genomes are flanked by the conserved 5’ and 3’ untranslated regions (UTRs). 
genomic RNAs. The intergenic region (IGR) separates the two genes on each RNA 
segment, and the hairpin structure of IGR is believed to provide the termination signal of 
transcription. 
The untranslated regions (UTRs) at the 5’ and 3’ termini of each RNA segment are 
conserved among arenaviruses. Like other negative-strand RNA viruses, these UTRs are 
complementary to each other and therefore can form panhandle structures (28). The 
UTRs also play an important role in viral nucleocapsid formation and favor the viral 
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Fig. 2 
 
Fig. 2. Arenaviral ambisense-genome replication strategy: due to the ambisense coding 
strategy of the arenaviruses, the NP (and L) genes are transcribed directly from the viral 
genomic segments into mRNAs, whereas the GP (and Z) mRNAs must be transcribed 
from the antigenomic strands after genome replication. 
polymerase recognition of the viral termini to initiate replication and transcription (28). 
2.2. Virus entry mechanisms 
The life cycle of arenaviruses starts with virus attachment and entry into cells (Fig. 3). 
The OW and NW clade C arenaviruses use α-dystroglycan (αDG) as their primary 
receptor (29, 30). Dystroglycan is a ubiquitously expressed glycoprotein that links cells to 
the extracellular matrix (ECM). It contains two non-covalently associated subunits, αDG, 
and βDG, which play different roles in virus attachment and cellular function. αDG is an 
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extracellular subunit that associates with ECM proteins such as laminin, agrin, perlecan, 
and neurxins. Upon virus infection, the viral glycoprotein 1 subunit (GP1) mediates 
attachment to the αDG, which allows the viral particles to internalize and deliver to the 
late endosomes. βDG is a transmembrane protein that binds to the cytoskeletal adaptor 




Fig. 3. Arenavirus life cycle. 1. Cellular entry is mediated by different cellular receptors 
(αDG for OW and NW clade C arenaviruses; TfR1 for NW Clade B). Entry of some 
viruses (e.g., LASV) may also involve a pH-dependent switch to an intracellular receptor 
(LAMP1) located in the lysosomes. 2. Virus uptake into cells is mediated by endocytosis 
(OW arenaviruses: clathrin-independent, NW: clathrin-dependent). 3. Virus fusion 
occurs with the late endosome. 4. Viral RNP is released into the cytoplasm via a pH-
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dependent membrane fusion mechanism. 5. Viral genome replication, transcription, and 
protein expression strictly occur in the cytoplasm. 6. Virion assembly and budding occur 
at the plasma membrane. 
 
αDG is a highly glycosylated protein, and studies have shown that post-translational 
modification of αDG is essential for viral binding (31). Many cellular enzymes are 
involved in these modification processes, including the cellular like-
acetylglucosaminyltransferase (LARGE), LARGE2, putative glycosyltransferases protein 
O-mannosyltransferase 1/2 (POMT 1/2), protein O-mannose β1,2-N-GlcNAc transferase 
1(POMGnT1), fukutin and fukutin-related protein (FKRP) (32). An in vivo study has 
shown that glycosylation is not critical for LCMV infection (33). However, this may be 
due to the in vivo compensation mechanism or the use of an alternate receptor. 
LCMV and LASV bind to the N-terminal and C-terminal domains of αDG in regions 
overlapping the binding site of laminin (34), which suggests that these viruses compete 
with laminin for αDG binding (35). Small peptides based on the binding site residues of 
laminin have been designed and shown to efficiently neutralize these viruses (36). 
Interestingly, upon infection by the OW arenaviruses, αDG is down-regulated from the 
cell membrane while the expression of the precursor DG remains unaffected.  This is 
mediated by the viral GP, which targets the interaction between DG and LARGE in the 
Golgi and thereby disrupts the proper glycosylation of αDG. However, this process may 
play an important role in viral release and not necessarily at the entry step (32, 37).   
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Animal studies and human clinical data have demonstrated high viral titers in the liver 
despite the fact that hepatocytes are not known to express αDG (38). Several cellular 
factors, including Axl, Tyro3, DC-SIGN, and LSECtin have been shown to play a role in 
LASV entry (39). While a recent study has shown that Axl does not necessarily play a 
major role for the establishment and maintenance of a persistent LCMV-ARM infection 
in mice (40), its expression is highly up-regulated in mice infected with the LCMV-WE 
strain that can induce transient liver pathology (41).  It is also interesting to note that 
skeletal muscle expresses high levels of αDG without any evidence of virus replication 
(42). A recent study has demonstrated that LCMV can replicate in myotubes, but that its 
entry is restricted in a similar manner as what has been known for avian cells that also 
express high levels of αDG but are resistant to arenavirus infection(43). More recently, 
the cellular lysosomal-associated membrane protein 1 (LAMP1) has been demonstrated 
as an intracellular receptor for LASV, and that a single glycosylation site of LAMP1 is 
critical for viral binding, which is absent in the birds (44). Therefore, entry of some 
viruses (e.g., LASV) may also involve a pH-dependent switch to an intracellular receptor 
(LAMP1) located in the lysosomes of human and mouse cells (44). It remains to be 
determined whether LAMP1 is required for the entry of other arenaviruses.  
The NW clade B arenaviruses use transferrin receptor 1 (TfR1) as their receptor (45). 
Five viruses in this clade, JUNV, MACV, GTOV, SABV, and CHAPV can cause HF 
infections due partly to their ability to bind to the human TfR1 receptor (45-48). In 
contrast, three other viruses in this clade, Tacaribe virus (TCRV), Amapari virus 
(AMAV) and Cupixi virus (CPXV) are non-pathogenic partly because they cannot bind 
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to hTfR1 but can still use TfR1 orthologs for entry (49). A recent study has demonstrated 
that the NW clade A/B arenaviruses use rodent TfR1 as viral receptor, but that some 
members of this arenavirus clade may also have the potential to use hTfR1 for entry (50-
52). Therefore, hTfR1 receptor usage alone is not the primary determinant of 
pathogenesis for NW arenaviruses. TfR1 is an iron-transferrin receptor that is regulated 
by the cytosolic level of iron. Upon transferrin binding to the TfR1, the complex is 
internalized and delivered to the acidic endosome via the clathrin-mediated pathway. At 
least three different viral families use TfR1 as host receptors (53, 54). These viruses use a 
similar strategy to gain the entry into cells (55). Under the low iron dietary condition in 
some endemic areas, in which TfR1 gene expression can be up-regulated, resulting in a 
suspected worse disease prognosis (56).  Some NW clade B arenaviruses may use 
alternative receptors for entry. For example, JUNV has been shown to use DC-SIGN and 
L-SIGN for virus binding and entry (57). 
Upon binding to the cellular receptor arenaviruses are internalized by vesicles, and are 
then released into the cytoplasm through a pH-dependent membrane fusion step that is 
accomplished by the transmembrane portion of the viral glycoprotein GP2 (58).  The 
arenaviral glycoprotein subunit 2 (GP2) is a class I fusion protein (59). However, 
different from other class I transmembrane proteins, the arenaviral glycoproteins (GPs) 
remain associated with the unusually long stable signal peptide (SSP) on the membrane. 
The interaction between SSP and GPs is required for the GP2 membrane-fusion function 
(60). The SSP helps keep the GP pre-fusion conformation in the natural environment and 
to facilitate the GP2 response to the acidified environment of the endosome. Interestingly, 
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some studies have shown that LCMV and LASV do not pass through the early endosome. 
Instead, these OW arenaviruses directly go into the late endosomes, thereby avoiding 
recognition by the host endosomal immune sensors in the early endosome. As such, 
infection by the OW arenaviruses, such as LASV, is able to suppress the innate immune 
response and produce significantly low levels of type I interferons (IFNs) at the early 
stage of the infection.  
Many studies have focused on the process of internalization of the virion particles into 
the late endosome. By gold labeling LCMV and visualizing it in a transmission electron 
microscope (TEM), LCMV has been found to locate in smooth and uncoated plasma 
membranes, close to the primary endocytic vesicles (61). Few viral particles are found to 
be associated with clathrin-coated structures. However, a separate study has demonstrated 
that LCMV infection is independent of clathrin, dynamin-2, actin, Arf6, flotillin-1, 
caveolae, and lipid rafts. The pathway to deliver LCMV and LASV into acidified 
endosomes is Rab5-independent but microtubular-dependent (61, 62). This pathway is 
associated with the cellular endosomal sorting complex required for transport (ESCRT) 
(62). This unusual pathway of virus internalization is related to the process of αDG 
receptor degradation (62).  
2.3. Viral genome replication and transcription   
Arenaviral genome replication and transcription occur in the cytoplasm of the infected 
cells (Figure 3).  Arenaviruses produce 3 types of RNA species: genomic RNA (gRNA), 
anti-genomic RNA (agRNA), and viral mRNA. While gRNAs and agRNAs are 
replicated as full-length RNAs, the mRNAs are transcribed from the promoter and 
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terminated by the highly structured IGRs (Figure 2). Because of the ambisense coding 
strategy, the NP and L mRNAs are directly transcribed from the gRNAs, but the GP and 
Z mRNAs can only be transcribed from the agRNAs. The NP and L proteins are 
necessary and sufficient to mediate viral RNA transcription and replication (63-65). 
The arenaviral L protein contains the viral RdRp, which can be divided into three or four 
domains based on different types of analysis (66-68). The four conserved RdRp residues 
are located in the central domain, which mediates viral gene transcription and 
replication(69). The C terminal domain of the L protein may be involved in viral mRNA 
synthesis process, the exact mechanism of which is unknown (70). The N terminal 
domain of the L protein has endonuclease activity (71, 72), which has been shown to be 
essential for viral gene transcription but not replication (71). Arenaviruses employ a “cap 
snatching” process to obtain the 5’ cap structure from cellular mRNAs for use to prime 
viral mRNA transcription (73). We and other researchers have recently determined the 3-
dimensional structures of the endonuclease domain of the LASV and LCMV L proteins 
(71, 72, 74). Both arenaviral NP and L proteins may be involved in this cap-snatching 
process. The N terminal domain of NP has a deep groove that can potentially bind the 
m7GpppN cap structure from the cellular mRNAs (74). This cap binding function of NP 
is believed to provide some arenaviruses (e.g., JUNV, TCRV, and PICV) with the ability 
to translate viral genes independently of the cellular eIF4E protein subunit of the eIF4F 
complex (75). The NP-NP and NP-L interactions also play an important role in mediating 
viral mRNA synthesis (76). Arenaviral matrix Z protein has also been shown to play an 
important regulatory role in viral RNA replication process (64, 77-79). Z can directly 
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interact with the viral L polymerase at the terminal panhandle RNA structure and thereby 
locking the polymerase in a promoter-bound catalytically inactive state to inhibit viral 
RNA synthesis (80). 
2.4. Post-translational protein processing   
The nascent viral GP precursor polypeptides are cleaved into the stable signal peptide 
(SSP) and the G1/G2 peptide in the endoplasmic reticulum (ER) by the cell signal 
peptidase (60, 81). The GP1/GP2 peptide remains associated with SSP in the ER until it 
is being cleaved further by the cellular protease subtilisin/kexin isozyme-1 (SKI-1)/site 1 
protease (S1P) into GP1 and GP2 subunits (81, 82). This process can take place in either 
the ER or Golgi (82-85). Both GP1 and GP2 contain several N-glycosylation sites, which 
are important for the correct glycoprotein complex (GPC) cleavage, maturation, and 
transportation. The LASV GPC contains six N-glycosylation sites that are essential for 
GPC cleavage, but other glycosylation sites do not seem to be directly involved in the 
proteolytic process (86). The myristoylation site on the G2 residue of the Z protein is 
important for the virus budding process due to Z homo-oligomerization (87). 
2.5. Virion assembly 
Like most enveloped negative-strand RNA viruses, the matrix protein mediates the virion 
assembly process, which depends in part on its late domain motifs (PPxY, PT/SAP, 
YxxL, θPxV, where x is any amino acid and θ is a hydrophobic amino acid) (88-90). 
Sequence analysis shows that most of the arenaviral Z proteins contain both the PT/SAP 
and YxxL motifs with most of the OW arenaviral Z proteins containing the PPxY motif.  
  14 
The interactions between Z and other viral and cellular proteins are important for the viral 
assembly and budding process (91). Several studies have revealed some important 
domains or residues that are important for these interactions. The myristoylation on the 
G2 residue is required for the membrane association of Z with GPC (92). The RING 
domain and the L79 residue of the TCRV Z protein are required for the interaction 
between NP and Z (93). The Z-NP interaction has also been shown for LCMV and LASV 
(94) and is mediated by the C terminal domain of NP (93, 95). We have confirmed that 
the G2 myristoylation site, the conserved cysteine and histidine residues of the RING 
domain, as well as the L79 and P80 residues in the C terminal domain, are essential for 
Pichinde arenavirus (PICV) replication(96). The interaction between Z and L has also 
been demonstrated (80, 87) as described above. The homo-oligomerization of Z has been 
shown to be important for virion budding (97). Finally, the interactions between the late 
domain motifs of the Z protein with the cellular ESCRT and/or ESCRT associated 
ubiquitin ligase help drive the virus budding process (98). The LCMV IRG has also been 
shown to be important for the viral assembly and budding process (99).  
3. Molecular mechanisms contributing to virus virulence and HF disease 
pathogenesis  
3.1. Roles of the glycoprotein (GP) and of the host cell receptors in HF disease 
susceptibility and pathogenesis 
The ability of virus binding to the different cellular receptors via its glycoprotein makes 
GP an important pathogenic factor. OW and NW clade C arenaviruses use alpha-
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dystroglycan (αDG) as their receptor for cell entry. The differences in affinity of GP 
binding to αDG may contribute to differences in the disease outcome. Two strains of 
LCMV, clone 13 (Cl 13) and Armstrong (ARM), can induce different disease outcomes 
in mouse models. The Cl 13 strain causes chronic infection, whereas the ARM strain 
causes acute infection. Studies showed that LCMV with high affinity for αDG, such as 
the Cl 13 strain, is able to infiltrate the white pulp of the spleen and abolish the cytotoxic 
T lymphocytes, therefore inducing a persistent infection. During the infection of αDG 
low-affinity strain, ARM strain, the viruses are mainly restricted in the red pulp and are 
quickly cleared by the strong cytotoxic T lymphocyte (CTL) response (34, 100).  
A recent analysis of over 3 million human genomic polymorphisms by the International 
HapMap Project has suggested a natural positive selection in a Nigerian population for 
allele variants of several human genes, including LARGE, interleukin 21 (IL21), and 
dystrophin (DMD), which is a cytosolic adaptor protein that is required for the proper 
function of αDG (101, 102). A high proportion of individuals in this population (21%) 
have shown evidence of prior exposure to LASV, which may apply selective pressure on 
the allelic frequencies of these human genes giving rise to their differential gene 
expressions that would confer natural resistance to Lassa fever. These polymorphisms in 
LARGE and DMD, for example, may have hindered binding and entry of LASV, and 
thereby protecting these individuals from severe LASV infection (101, 102). 
NW clade B arenaviruses include both pathogenic and non-pathogenic viruses. Among 
this group of viruses, JUNV, MACV, GTOV, SABV, and CHPV can cause severe and 
lethal HF in humans (17, 18, 21, 25, 103, 104). All five of these pathogenic NW clade B 
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arenaviruses use human transferrin receptor 1 (hTfR1) as their receptor for cellular entry 
(3). In contrast, the known NW clade B non-pathogenic viruses can only use the rodent 
version of TfR1 as their receptor. Likewise, the NW clade A/B viruses also use the host-
species specific TfR1 as their receptors (3). Virion RNAs with sequence homology to the 
Whitewater Arroyo virus (WWAV), a clade A/B virus, has been detected in several 
human cases, suggesting that WWAV might be associated with human infections.  While 
some studies have shown that this virus is unable to use hTfR1 as an entry receptor (105, 
106), WWAV-like viruses have been shown to potentially use hTfR1 as a receptor (3). 
However, it is not clear whether usage of hTfR1 plays any role in disease pathogenesis, 
as WWAV has not directly been shown to be a causative HF agent. 
Further evidence for the involvement of GPC as an important determinant of arenavirus 
virulence has been demonstrated in the guinea pig model for PICV infection (107).  Two 
strains of PICV (P2 and P18) can cause vastly different disease outcomes in infected 
animals (108, 109). Mutational analysis of the virulent (P18) and avirulent (P2) strains 
has revealed that sequence differences between the GPCs may contribute to the different 
disease outcomes. Substituting a single amino acid residue at position 140 of GPC from 
the avirulent P2 into the virulent P18 genome can increase the survival rate of infected 
animals from 0% to 33%, suggesting that GPC plays an important role in the disease 
outcomes (107).  A separate study has shown that mutational analysis at residue 427 of 
the GPC of the attenuated Candid #1 strain of JUNV is largely responsible for the 
attenuation of this vaccine strain in suckling mice (110). That the residue change at this 
site results in increased virus-cell fusion at neutral pH of the Candid #1 strain and also in 
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increased dependence on hTfR1 for entry demonstrates its role in contributing to virus 
attenuation in humans (111). The study of the ML29 vaccine, a reassortant virus 
consisting of the LASV S genomic RNA segment and the Mopeia (MOPV) L genomic 
RNA segment, shows the attenuated phenotype of this reassortant virus in non-human 
primates and guinea pigs (112, 113). This data suggests that the major virulence factor(s) 
of LASV is located on the L segment. Other virus reassortant studies using LCMV or 
PICV have also implicated the contribution of the L genomic RNA segment in viral 
pathogenesis (114-116). While the L polymerase gene, encoded on the L segment may 
play an important role, it is important to note that the L segment also encodes the Z 
protein with known roles in regulating RNA synthesis and host innate immunity that can 
participate in disease pathogenesis (77, 80, 117, 118). Interestingly, sequence analysis of 
the ML29 viruses isolated from infected animals reveals several important mutations on 
the S segment, especially within the GP coding sequence. The K272E mutation located 
between the SKI-1/S1P cleavage site and GP2 fusion domain is one such mutation (119). 
It remains to be determined whether this and perhaps other mutations within the GP gene 
or elsewhere on the S segment of the ML29 vaccine virus contribute to the reduced 
pathogenic phenotype observed for this reassortant virus.  
3.2. Role of the polymerase (L) protein in viral virulence  
A hallmark of severe and lethal arenavirus-induced HF is the high level of viremia. It has 
been shown that individuals who can control the level of viremia are able to recover from 
the infection, while those who cannot typically succumb to the disease (120).  A single 
amino acid in the L polymerase (L1079) of the LCMV Cl13 has been shown to enhance 
  18 
the levels of intracellular viral replication, which can account for the difference of viral 
replication rates between the ARM and Cl 13 strains (121). This residue has also been 
shown to be responsible for generalized immune suppression, which is likely a result of T 
cell exhaustion caused by the high viral loads, and therefore may be responsible for the 
difference in acute versus chronic infection by the ARM and Cl 13 strains.  A separate 
study has shown that this same residue is responsible for enhanced viral replication and 
tropism in macrophages (122). Using reverse genetics technology, we and other 
researchers have also demonstrated the role of the L polymerases of LASV and PICV in 
increasing viral replication and virulence in infected animals (123, 124). We show that 
the C terminal domain of L polymerase is the virulence determinants of PICV P18 strain. 
In particular, three residues (N1906, N1889, and L1839) in the C terminal domain are 
associated with increased viral replication and pathogenesis in infected animals (124). It 
is important to note that all naturally occurring residues found to enhance virus 
replication in LCMV, LASV, and PICV do not map to the known catalytic domains of 
the polymerase, and therefore their exact contributions to increased viral RNA synthesis 
and disease pathogenesis have yet to be determined.  
3.3. Role of the nucleoprotein (NP) in innate immune suppression 
Host immune responses to infection have a profound and direct influence on the disease 
course and outcomes. One of the hallmarks of severe and lethal arenavirus-induced HF is 
generalized immune suppression, the mechanisms of which are still under intense 
investigation. The nucleoproteins (NPs) of several arenaviruses have been shown to be 
capable of inhibiting the host innate immune responses. Specifically, the NPs of the OW 
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arenaviruses LCMV, LASV and the NW arenaviruses JUNV, MACV, WWAV, PICV, 
TCRV, and LATV have been shown to inhibit the production of interferon-beta (IFNβ) 
(125, 126).  
Using x-ray crystallography and various functional assays, we and other researchers have 
demonstrated that the C terminus of the NPs of LASV, TCRV, and PICV contains a 
functional 3’-5’ exoribonuclease (RNase) domain that degrades dsRNA in vitro (74, 126, 
127). We have therefore proposed that NP inhibits type I IFNs by degrading viral pattern-
associated molecular pattern (PAMP) molecules that would otherwise be recognized by 
cellular pattern recognition receptors (PRRs). The fact that the DEDDH catalytic residues 
are conserved among all known arenaviruses and that its function to suppress IFNβ 
production has been demonstrated for both pathogenic (e.g., LASV and LCMV) and non-
pathogenic arenaviruses (e.g., TCRV and MOPV) suggests that this is a general 
mechanism of innate immune suppression by these viruses allowing them to replicate in 
either their natural hosts (e.g., rodents) or in infected humans. 
Amino acid substitutions of the conserved RNase catalytic residues (DEDDH) 
significantly reduce NP’s ability to inhibit IFNβ production in virus-infected cell cultures 
and in animals, directly implicating the exoribonuclease function in innate immune 
suppression (74, 126) We have recently generated recombinant PICVs carrying 
individual NP RNase catalytic mutations (D380, E382, D457, D525, or H520) (128). In 
vitro studies of these mutant PICVs show that these viruses induce high levels of IFNβ 
and grow poorly in the IFN competent A549 cells, but they can grow to similarly high 
titers as that of the wild-type PICV in IFN-defective Vero cells. All the RNase catalytic 
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mutant viruses show an attenuated phenotype in infected guinea pigs, but show reversion 
to the wild-type NP sequence in isolates from moribund animals, providing strong 
genetic evidence for the important role of the NP RNase function in suppressing innate 
immunity and allowing the virus to replicate in the infected animals. This is consistent 
with another study in which a recombinant LASV carrying a double-point mutation of the 
NP RNase catalytic residues (D389 and G392) replicates to lower titers than the wild-
type virus partly because it is unable to suppress type I IFNs (129). The same group of 
investigators has also recently demonstrated that the LASV NP RNase domain is required 
to mount an effective antigen-presenting-cell-mediated response in NK cells against virus 
infection (130). Other studies have suggested that when NP is overexpressed in cells, 
they can either prevent activation of the Nuclear Factor Kappa B (NFB) or directly 
associate with RIG-I or IKKε in order to inhibit the phosphorylation the IKKε or of the 
IFN-responsive gene (IRF3) and its translocation into the nucleus and thereby negatively 
regulates type I IFN production (131-133). Taken together, these data confirm the critical 
role of the arenaviral NP in mediating innate immune suppressive function that would 
then allow the virus to replicate unchecked. While the generalized immunosuppression 
and high viremia are important factors in arenavirus-induced HF pathogenesis, it is 
important to note that many individuals infected with pathogenic arenaviruses (e.g., 
LASV) do recover from the infection as a result of a robust cell-mediated immunity (4, 
6). 
3.4. Roles of the Z protein in innate immune suppression and viral pathogenicity 
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In addition to mediating viral budding and regulating viral RNA synthesis (see above), 
the Z protein also has immune suppressive function. A previous study has shown that the 
Z proteins of NW arenaviruses (JUNV, MACV, TCRV, and SABV), but not OW 
arenaviruses LASV and LCMV, can interact with the cytoplasmic pathogen-recognition-
receptor RIG-I to inhibit the type I IFN induction (118). We have recently conducted a 
comprehensive analysis of the Z proteins from many known arenaviruses and have found 
that the Z proteins of all 9 known pathogenic arenaviruses, including LASV, LCMV, 
LUJV, JUNV, MACV, TCRV, SABV, and DANV, can effectively suppress the RIG-I-
like receptor (RLR)-induced IFNβ responses (117). This Z-mediated RLR inhibition is 
strongly associated with arenavirus pathogenicity, as only the Z proteins of all known 
pathogenic arenaviruses, but not any of the 14 non-pathogens, can inhibit human RLRs 
(117).  The inhibition is mediated by the interaction between the flexible N-terminal 
domain (NTD) of the pathogenic Z proteins and N-terminal tandem CARD domains of 
RIG-I/MDA5, and thus disrupting the association of the RLRs and the mitochondrial 
antiviral signaling protein MAVS. Swapping of the 31-residue Z NTD from LCMV into a 
nonpathogenic PICV genome has led to the inhibition of type I IFN responses and 
increased viral replication in human macrophages – the early target cells of arenavirus 
infections. This study indicates that the pathogenic Z-mediated RLR inhibition by 
arenaviruses may be a common pathogenic mechanism underlying the diverse arenavirus 
family to cause diseases in humans. While each arenavirus pathogen may have its unique 
pathogenesis leading to variable disease symptoms in humans, all of them encode a Z 
protein that can inhibit the RLR signaling and thus, the induction of type-I IFNs.  
  22 
4. In vivo and in vitro primary cell-culture models of arenavirus-induced HF disease 
pathogenesis 
4.1 Human primary cell-culture models 
Macrophages and dendritic cells (DCs) are known early target cells of arenavirus 
infection. Several studies have suggested that pathogenic arenaviruses (e.g., LASV and 
JUNV) and non-pathogenic viruses (e.g., MOPV and TCRV) can differentially inhibit 
human macrophages but they all can inhibit DCs (117, 134-138), the molecular 
mechanism of which is not yet clearly understood. Both LASV and MOPV have shown 
to be capable of infecting primary human macrophages and DCs, but intriguingly the 
pathogenic LASV does not activate these cells upon infection. In sharp contrast, infection 
of macrophages by the non-pathogenic MOPV activate these cells as demonstrated by 
increased expression levels of activation markers CD86, CD80 and IFNβ (137). 
Similarly, primary human macrophages show higher IL-6, IL-10 and TNF production 
upon infection by the nonpathogenic TCRV as compared to the pathogenic JUNV 
infection (138). Consistent with these data, our laboratory has recently shown that the Z 
proteins of all known pathogenic arenaviruses are able to inhibit activation of 
macrophages, unlike those Z proteins from most known non-pathogenic arenaviruses 
(117). Since macrophages and DCs are professional antigen-presenting cells that offer the 
first line of defense against viral infections, inhibition of these immune cells can induce a 
general immune suppression of both the innate and adaptive arms of immunity that 
undoubtedly impact HF disease pathogenesis. Additional studies to investigate the 
mechanism(s) of immune responses of macrophages and DCs to pathogenic and 
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nonpathogenic arenaviruses are therefore warranted in order to elucidate the interplays 
between these virus pathogens and host immunity in driving HF disease pathogenesis. 
4.2. Surrogate and non-human primate models 
Although the pathogenesis of Lassa fever is still not clearly understood, severe LASV 
infection in humans often results in high levels of viremia, lymphopenia, functional liver 
damage, vascular abnormalities and profound suppression of both innate and adaptive 
immune responses (6)  Different laboratory animal species have been used to mimic key 
pathophysiological features of human HF diseases (139-141).  For example, guinea pigs 
have been used to study arenavirus-induced lung pathology (142, 143), while common 
marmosets (144) and LCMV-WE-infected rhesus macaques have been used to study 
arenavirus-induced liver pathology. Due to the strict requirement to work with the highly 
pathogenic arenaviruses (e.g., LASV) in the high biocontainment (BSL-4) facilities, 
surrogate animal models of arenaviral HF that involve infection of guinea pigs with the 
PICV, a risk group 2 pathogen, has been established in outbred Hartley as well as inbred 
strain 13 guinea pigs to study some mechanisms of Lassa fever-like disease pathogenesis 
(108, 145, 146). When outbred Hartley guinea pigs were infected with a low passage 2 
(P2) strain of PICV, it induced a mild disease, whereas a highly adapted P18 strain 
(passaged 18 strain) of PICV caused a fatal disease with symptoms mimicking some 
features of Lassa fever, including but not necessarily limited to suppression of 
proinflammatory cytokines that was associated with terminal shock and death. While 
these surrogate animal models can serve as a relatively inexpensive and safe alternative 
for studying HF disease pathogenesis, the immune system of these rodents can be 
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fundamentally different from those of humans and non-human primates (NHPs). LASV-
infected rhesus and cynomolgus monkeys are therefore considered the gold-standard 
models to study Lassa HF disease pathogenesis (147-154). Recent studies focusing on 
early stages of Lassa fever in NHPs and immune responses (152, 155) have confirmed 
previous observations on several factors important in HF disease pathogenesis, including 
high viremia, elevated liver enzymes, low or undetectable levels of proinflammatory 
cytokines (IL-1β, TNF-α, IL-8 and IP-10), and low and/or ineffective T-cell activation. 
These studies also show that early and strong T-cell responses are associated with 
effective control of virus replication and recovery. However, much work still needs to be 
done in order to understand the molecular mechanism(s) underlying HF disease 
pathogenesis in these animal models. 
5.  Conclusions 
Arenaviruses are RNA viruses with a relatively simple genomic structure but with a 
complex biology and pathogenic mechanisms. The genome of the viruses encodes for 
only four genes, but each viral protein has multiple functions to mediate optimal viral 
replication and is possibly involved in the determination of different disease outcomes in 
humans. Studies have suggested that arenaviruses can gain virulence in the hosts by 
increasing viral cell entry and replication capacity and by effectively suppressing host 
innate immune responses. The recent identification of the Z protein as a pathogenicity-
associated factor has shed important insights into a common pathogenic mechanism 
underlying the diverse human arenavirus pathogens. Nevertheless, different human 
arenavirus pathogens exhibit unique features in basic viral replication mechanisms and 
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disease manifestations(4), suggesting that further studies are warranted in order to 
understand the virus-specific pathogenic mechanisms for individual arenavirus 
pathogens. Important insights from recent studies on this group of important human 
pathogens can be exploited for the development of effective preventative and/or 
therapeutic modalities that can be tested in some established animal models of arenaviral 
HF. 
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Chapter II 
Characterization of the Glycoprotein Stable Signal Peptide in Mediating Pichinde 
Viral Replication and Virulence 
Introduction 
Arenaviruses can cause neurologic or hemorrhagic fever diseases in humans with limited 
preventive or therapeutic measures (156, 157). The most significant arenavirus pathogen 
is Lassa fever virus (LASV), which causes endemic infections in many countries in West 
Africa with estimated 500,000 cases resulting in ~5000 deaths annually (158). Except for 
Junin virus (JUNV), which has a vaccine Candid#1 used only in Argentina, no licensed 
vaccine for human usage is currently available for any other arenaviruses. Therapeutic 
options are limited and depend mainly on supportive cares. Ribavirin, a non-specific 
antiviral compound, has shown some efficacy only if it is administered at an early stage 
of viral infection when the symptoms are insidious (159). Development of effective 
vaccines and antivirals against arenavirus pathogens is therefore urgently needed.  
Arenaviruses are enveloped, bi-segmented ambisense RNA viruses (160). Each viral 
genomic segment encodes two viral gene products. The large RNA segment (L) encodes 
viral RNA-dependent RNA polymerase L protein and the multifunctional protein Z. The 
small RNA segment (S) encodes nucleoprotein (NP) and glycoprotein (GPC). GPC is 
expressed as a single polypeptide with a long stable signal peptide (SSP) and is post-
translationally processed by the S1P cellular protease into the receptor-binding GP1 and 
transmembrane GP2 subunits (161, 162). The 58-aa conserved SSP contains an N-
terminal G2 myristoylation site, two hydrophobic domains (h1  and h2) separated by an 
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ectodomain, and a C-terminal SP cleavage site (Fig. 4A) (163), although the exact 
boundaries of these domains have not been well defined (164, 165). SSP is an essential 
component of the envelope glycoprotein complex and plays important roles not only in 
regulating the intracellular trafficking and proteolytic maturation of GPC, but also in the 
pH-induced membrane-fusion reaction (166, 167). However, the biological roles of SSP 
in arenavirus infection in vitro and in vivo have not been investigated. 
Pichinde virus (PICV) is a non-pathogenic BSL2 agent and its infection of guinea pigs 
has been used as a safe, convenient, and economic small animal model for Lassa fever 
(168, 169). A low passaged strain of PICV (i.e., P2) causes a brief febrile reaction in 
guinea pigs, while a high passaged strain (i.e., P18) causes a severe Lassa fever-like 
disease in guinea pigs with high mortality (158, 168-172). We have developed the 
infectious clones for both the non-virulent P2 strain and the virulent P18 strain of PICV 
(173), and characterized the virulence determinants at the molecular level (107, 124, 
146). 
In this study, we investigate the biological roles of the conserved residues of the SSP in 
vitro and in vivo by using the PICV reverse genetics system. Many of these residues have 
been previously characterized in the context of GPC expression and pseudotyped viruses 
(163, 165, 174-177), however, their biological roles have not been investigated.  Here, we 
show that multiple SSP conserved residues are essential or critical for viral infection of 
cell culture and/or guinea pigs by participating in the membrane fusion reaction, and that 
two residues N37 and R55 are required for viral virulence by a yet-to-be-determined 
mechanism.   
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Results 
Effects of SSP mutations on GPC expression and processing. 
Sequence alignment of SSPs among 22 different arenaviruses identified 8 residues that 
are either completely or highly conserved (Fig. 4A): two at the N-terminal end (G2 and 
Q3), one within the h1 domain (N20), one in the loop region (K33), two within h2 
domain (N37 and F49), and two at the C-terminal end (R55 and C57). We introduced 
alanine substitutions at each of these conserved residues in the PICV GPC expression 
vector pCAGGS-PICV-GPC. We first examined whether each GPC mutant was 
expressed and processed properly after transfecting 1 μg of each plasmid into 293T cells 
and conducting a Western blot analysis with guinea pig anti-PICV antiserum, which 
detects both the polyprotein precursor GPC and the cleaved products GP1/GP2 but not 
SSP. The cleavage efficiency of each construct was calculated by dividing the amount of 
the cleaved products (GP1/GP2 subunits) over the total amount of the proteins (GPC 
precursor and GP1/GP2). Mutants G2A, Q3A, K33A, N37A, and R55A showed similar 
levels of expression and cleavage efficiency as the WT GPC (Fig. 4B, left panel). While 
N20A GPC precursor was expressed at a relatively high level, the GP1/GP2 cleavage was 
significantly reduced (Fig. 4B, left panel). Both F49A and C57A GPC precursors were 
expressed at much lower levels and their GP1/GP2 processing was undetectable (Fig. 4B, 
left panel). Even after transfecting 4x more of the F49A or C57A plasmid (at 4 μg each), 
we could not detect any significant GP1/GP2 cleavage products (Fig. 4B, right panel), 
suggesting that these two mutations severely impaired GPC processing. In summary, 
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among all conserved residues within the SSP, residues N20, F49, and C57 play an 
important role in regulating GP1/GP2 cleavage activity.  
We next detected GPC assembly at the cell membrane by staining the transfected 293T 
cells with anti-PICV antiserum and FITC-conjugated secondary antibody without 
permeabilization. Representative histograms of empty vector- and WT GPC-expressing 
cells are shown in Fig. 4C (left panel). Using this method, we showed that, with the 
exception of F49A and C57A, there was no statistical significance in the surface 
expression levels of GPCs between WT and GPC mutants (Fig. 4C, right panel). In 
particular, N20A had a similar level of surface expression as WT (Fig. 4C) even though it 
was defective in the GP1/GP2 cleavage activity (Fig. 4B). For F49A and C57A, the 
reduced surface levels (~ 25% of WT) (Fig. 1C) were most likely due to the diminished 
total protein expression levels (~ 20% of WT) (Fig. 4B) and not because of any block(s) 
in the intracellular trafficking. The differential effects of F49A and C57A on the GPC 
trafficking between our results of the PICV GPC and other published studies on JUNV 
and LCMV GPC (176, 178) may reflect the potential topological and/or biological 
differences between the GPCs. In summary, our data suggest that most (six out of eight) 
of the SSP conserved residues do not affect the intracellular transport or surface 
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Fig.4    
 
FIG. 4. Effects of SSP mutations on GPC expression, GP1/2 cleavage, and cell surface 
expression. (A) Sequence alignment of arenavirus GPC SSP regions (left) and the 
topology of SSP with two transmembrane domains, h1 and h2, shown (right). Conserved 
residues are indicated by arrows. Abbreviations: MOBV, Mobala virus; IPPYV, Ippy 
virus; FLEV, Flexal virus; PARV, Parana virus; ALLV, Allpahuayo virus; PIRV, Pirital 
virus; TCRV, Tacaribe virus; CPXV, Cupixi virus; AMAV, Amapari virus; MACV, 
Machupo virus; GTOV, Guanarito virus; SABV, Sabia virus; LATV, Latino virus; 
WWAV, Whitewater Arroyo virus; TAMV, Tamiami virus; BCNV, Bear Canyon virus. (B) 
Expression and processing of wild-type (WT) and mutant PICV GPCs. Expression 
vectors of WT or SSP mutants (1 µg of plasmid DNA unless otherwise indicated) were 
transfected into 293T cells. Cell lysates were analyzed by Western blotting with guinea 
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pig anti-PICV antisera. Actin expression was used to monitor equal sample loading 
efficiency. (C) Cell surface expression of WT and mutant PICV GPCs. Shown on the left 
are representative FACS histograms for the vector or WT GPC-transfected cells after 
immunofluorescence staining with anti-PICV antisera. Shown on the right are the 
averages and standard deviations of GPC surface expression from three independent 
experiments. Statistical analyses were conducted with Student’s t-test. ns, not statistically 
significant; ***, P<0.001. 
 
Effects of SSP mutations on GPC-mediated fusion activity 
To evaluate the effects of individual SSP mutation on the GPC-mediated membrane 
fusion activity, we conducted both syncytia formation and luciferase-based (luc-based) 
fusion assays. For syncytia formation assay, 293T cells were transfected with a GFP 
expression plasmid, which allows for easy detection of the transfected cells, together with 
either an empty vector control or the individual GPC plasmid. Cells were exposed to low 
pH environment and observed for syncytia formation under fluorescence microscopy. 
Compared to the vector control (negative), WT GPC expression led to the efficient 
formation of syncytia as evidenced by enlarged cells (Fig. 5A). Syncytia formation was 
also observed for Q3A, N37A, and R55A mutants (albeit to different levels), but not for 
G2A, N20A, K33A, F49A, and C57A mutants. To quantify the levels of GPC-mediated 
fusion activities, we used a luc-based fusion assay as described previously (166). GPC-
mediated membrane fusion allows for the transfer of the T7 RNA polymerase from 
BSRT7-5 cells to transcribe the T7 promoter-driven luc reporter gene from the 
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transfected 293T cells. Luc activity was measured for each of the GPC mutant constructs 
and normalized to the WT GPC control, which is set as 100% fusion efficiency (Fig. 5B). 
Consistent with the syncytia formations shown in Fig. 5A, mutants Q3A, N37A and 
R55A induced relatively high levels of luc activities as a result of GPC-mediated 
membrane fusion activities (Fig. 5B). The Q3A and R55A mutants appeared to be even 
more fusogenic than the WT, the reason(s) for which are unknown. In contrast, N20A 
had a significantly lower level of fusogenic activity, whereas G2A, K33A, F49A, and 
C57A did not exhibit any obvious fusogenic activity in this assay. Our data are consistent 
with previous studies, which have demonstrated that K33A, F49A, and C57A lead to a 
nearly complete loss of fusogenic activity of JUNV GPC (175, 178, 179). K33 has been 
shown to play a critical role in mediating membrane fusion (175, 180, 181). As F49A and 
C57A are defective in the GPC processing (Fig. 4B), the uncleaved GP1-GP2 precursor 
may not be able to expose the fusion peptide at the N-terminal GP2 subunit under low 
pH, which may explain the lack of fusogenic activity of the two mutants.   
Fig. 5. 
 
Fig. 5. Effects of SSP mutations on membrane fusion activity. (A) GFP-based fusion 
assay. Cells were transfected with a plasmid expressing eGFP together with either an 
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empty vector (negative) or plasmids expressing WT or individual mutant PICV GPCs. 
Cells were treated with low-pH medium to trigger membrane fusion. (B) Luc-based 
fusion assay. Luciferase activity mediated by membrane fusion by each of the GPC 
mutants in the fusion assay was determined and normalized to the activity mediated by 
the WT GPC, which is set at 100%. Results shown are the averages from three 
independent experiments with standard deviations. 
 
Effects of SSP mutations on GPC-mediated cell entry 
To compare the cell entry efficiency mediated by different GPC mutants, we generated 
lentivirus-like particles (VLPs) that contain WT or mutant GPC proteins using an 
established three-plasmid HIV-based system (182). Using the levels of HIV-1 p24 capsid 
protein on the VLPs for normalization purpose (Fig. 6A), similar amounts of GPC-
pseudotyped VLPs were used to transduce 293T cells. It is worth to note that F49A and 
C57A VLPs contained much less GP1/GP2 (Fig. 6A), consistent with their defective 
GPC processing (Fig. 6B). As the VLPs encode the eGFP gene, its expression in the 
VLP-transduced cells was quantitatively evaluated by flow cytometry (Fig. 6B). The 
G3A and N20A GPC mutants showed similar levels of transduction efficiency (15-20%) 
as WT, whereas the G2A mutation reduced the entry efficiency by 50%, and the K33A, 
F59A, and C57A mutations almost completely abolished the cell entry. In contrast, the 
N37A and R55A mutants led to even higher efficiency in cell entry than the WT GPC, 
the molecular mechanism(s) for which are unknown. In summary, using the GPC- 
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pseudotyped VLP system, we have shown that some of the SSP mutations (i.e., K33A, 
F49A, C57A, and G2A) significantly impair GPC-mediated cell entry. 
Fig. 6. 
 
FIG. 6. Effects of SSP mutations on GPC incorporation into VLPs and GPC mediated 
cell entry. (A) Lentiviral particles pseudotyped with respective GPC constructs were 
analyzed by Western blotting with guinea pig anti-PICV antiserum and anti-HIV p24 
antibody. (B) The percentage of GFP-positive cells after VLP transduction with the 
respective GPC-pseudotyped VLPs is shown as the average from three independent 
experiments with standard deviations. 
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Effects of SSP mutations on viral growth in vitro 
To examine the biological roles of the SSP conserved residues in arenavirus replication 
cycle, we created the same series of alanine substitutions in the GPC gene of the S 
segment of the PICV (P18 strain) reverse genetics system (173). Together with the L 
plasmid, each S plasmid expressing WT or mutant SSP was transfected into BSRT7-5 
cells in order to rescue recombinant viruses. We successful rescued and amplified 
recombinant viruses with the individual mutations G2A, Q3A, N20A, N37A, and R55A, 
but failed to rescue viruses with K33A, F49A, or C57A mutations even after repeated 
attempts (Fig. 7A), suggesting that K33, F49, and C57 are essential for PICV life cycle. 
We sequenced the viable mutant viruses after passaging four times in cell culture and did 
not detect WT reversion.  
We then compared viral growth ability between the WT and viable mutant viruses in 
BHK-21 cells at MOI of 0.01 (Fig. 7B, left). Four mutants (Q3A, N20A, N37A, and 
R55A) showed similar growth kinetics as WT, while G2A grew 0.5 - 1 log lower than 
WT, suggesting that the G2 residue plays an important role in viral replication.  Similar 
results were obtained in human lung epithelial A549 cells (Fig. 7B, right). As N20A 
mutation significantly reduced the GPC processing in a protein expression system (Fig. 
4B) but did not seem to affect viral growth in vitro (Fig. 7B), we wonder whether N20A 
indeed impaired the GPC processing in the context of viral infection. We infected BHK-
21 cells with WT or N20A virus at MOI of 10 for 24 h and analyzed cell lysates by 
Western blot using the anti-PICV antisera, anti-NP antibody, and anti-actin antibody, 
respectively (Fig. 7C). WT and N20A showed similar levels of NP, consistent with their 
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similar virus replication levels. The cleavage efficiency, which was calculated as the 
percentage of the cleaved products (GP1/GP2 subunits) over the total amount of the 
proteins (GPC precursor and GP1/GP2), was much lower in the N20A- than that in the 
WT-infected cells (Fig. 7C). Our results demonstrate that N20A significantly reduces the 
GPC processing in both protein expression system (Fig. 4B) and viral infection (Fig. 7C). 
Fig. 7 
 
FIG. 7 Rescue of recombinant PICV with WT or mutant SSP. (A) Summary of 
recombinant virus rescue efforts for each SSP mutant. (B) Viral growth curve analysis in 
BHK-21 (left) and A549 (right) cells. Vero cells were infected (MOI of 0.01) with WT or 
recombinant PICV mutants carrying respective SSP mutations. Viral titers in the 
supernatants at various time points postinfection were quantified by plaque assay. 
Results shown are averages and standard deviations from three independent experiments. 
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(C) GPC processing in virus-infected cells. A549 cells were mock infected or infected 
with the WT or N20A mutant at anMOIof 10. At 24 h postinfection, cell lysates were 
analyzed by Western blotting with guinea pig anti-PICV antisera, anti-NP antibody, and 
anti-actin antibody. The GPC processing efficiency is calculated as the percentage of 
GP1/GP2 over total GPCs. 
 
Effects of SSP mutations on viral virulence in vivo 
We determined the degrees of virulence of the recombinant SSP mutants in an 
established guinea pig model (168, 172, 173). Consistent with our previous observations 
(173), all animals (n=6) infected with the WT virus experienced a long duration of fever 
(average of 9 days), significant body weight loss, and reached terminal points by 14 dpi  
(Fig. 8). In contrast, all animals (n=3) infected with G2A or N20A mutant virus survived 
the infection with no obvious body weight loss as compared to the PBS control group 
(Fig. 8A and 8B). The G2A-infected animals also experienced significantly less days of 
fever (average of 3.8 days, Fig. 8C) than the WT-infected animals. Similarly, the N20A 
virus infection led to, on average, a shorter duration of fever than WT virus infection, 
though the difference is not statistically significant due to the relatively small number of 
the infected animals (Fig. 8C). In summary, both the G2A and N20A mutant viruses 
almost completely lost virulence in vivo (Fig. 8A).  
Infection with the Q3A mutant virus (n=7) led to ~ 90% mortality, substantial loss of 
body weight, and prolonged fever in guinea pigs, without significant difference from the 
WT virus infection (Fig. 8), demonstrating that the Q3A mutation does not greatly 
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attenuate the virus in vivo. On the other hand, animals (n=6) infected with either the 
N37A or R55A mutant virus experienced prolonged fever and variable degrees of body 
weight loss, with a survival rate of 30%-50% that is significantly higher than those 
infected with the WT virus (Fig. 8). Collectively, our data suggest that both the N37A 
and R55A mutant viruses are attenuated in vivo. It is worth mentioning that, for all 
mutant viral infections, animals that survived the infection did not contain any trace of 
infectious virus in the serum while all moribund animals had high viremia as determined 
by plaque assay, correlating with the previous reports that arenavirus virulence is 
associated with high levels of viral replication in vivo (124, 158, 183). We also 
sequenced all mutant viruses isolated from animals and did not detect any WT revertants. 
Fig. 8. 
 
FIG 8 Effects of SSP mutations on PICV virulence in guinea pigs. (A) Survival curve of 
guinea pigs infected with either the WT or respective SSP mutant viruses. Statistical 
analyses of the survival curves were performed using the log-rank (Mantel-Cox) χ2 test 
and/or Fisher’s exact test. (B) Daily body weight normalized to day 0 (set at 1.0). For the 
PBS, WT, G2A, and N20A groups, average body weights of each group are shown 
because all animals in the same group had similar trends in body weight change. The 
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Q3A group had one animal that survived the infection, and its body weight is shown 
separately from the average for the other 6 animals. The body weights of each animal in 
the N37A and R55A groups are shown. (C) The average duration of fever (rectal 
temperature of >39.8°C). Statistical analyses were conducted with Student’s t-test. ns, 
not statistically significant; *, P <0.05; **, P <0.01; ***, P< 0.001. 
 
Discussion 
In this study, we have determined the biological roles of 8 completely conserved residues 
of GPC SSP among all known arenaviruses, using PICV reverse genetics system. Table 1 
shows the effects of alanine substitution of each conserved SSP residue on the expression 
and function of GPC as well as on viral infections in vitro and in vivo. Except for N20A, 
F49A, and C57A, other SSP mutations do not affect the levels of GPC expression, 
GP1/GP2 cleavage, or surface assembly of the glycoprotein complex (Fig. 4). However, 
multiple SSP conserved residues are essential for viral infection by participating in viral 
entry, while two residues (N37 and R55) are important for viral virulence by a yet-to-be-
determined mechanism(s).  
Table 1. 
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a, ++++ higher than the WT level; +++, WT level; ++, significantly less than the WT 
level; +, minimally detected; -, undetectable; NA, not applicable. 
b, Virus rescue is the ability to rescue recombinant mutant virus: + indicates rescue of 
mutant virus; - indicates inability to rescue mutant virus. 
 
K33, F49, and C57 are required for viral entry and indispensable for PICV life cycle. Our 
results correlate well with prior studies of other arenaviruses, such as JUNV and the 
Lymphocytic Choriomeningitis virus (LCMV) (163). The K33 residue has been shown to 
play an essential role in GPC fusion by interacting with GP2 to prime the complex for 
pH-induced membrane fusion (163, 175, 177). The F49 residue is located within the 
recently identified FILL sorting signal motif that is required for glycoprotein processing 
and surface expression (163, 178). The C57 residue of the GP2 along with its H459, 
C467, and C469 residues form a zinc-binding center, which provides the structural basis 
for association with SSP in the glycoprotein complex in order to modulate optimal 
membrane fusion activity (179, 184).  
Another residue critical for viral fusion is the G2 myristoylation site. The myristoylation-
defective G2A mutation almost completely abolishes the fusion activity based on the cell-
based fusion assay (Fig. 5). It is, however, worth to mention that the fusion assay cannot 
fully reproduce the fusion activity of GPC during viral entry and therefore the result does 
not exclude the possibility that G2A mutation may retain a low level of fusogenic 
activity. Indeed we show that G2A GPC-pseudotyped VLPs can still mediate cell entry, 
albeit at a reduced level (Fig. 7B). As such, the G2A mutant virus can be rescued but is 
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significantly attenuated in vitro and in vivo (Figs. 7-8). Previous studies of JUNV and 
LCMV GPCs have also shown that the G2A mutation can markedly reduce the 
membrane fusion activity (163, 185). The molecular mechanism by which the G2 
myristoylation site is involved in viral membrane fusion remains unknown. 
Myristoylation plays an important role in membrane targeting and protein-protein 
interactions (186). We and others have shown that GPC with the G2A substitution is still 
able to express properly and to assemble at the plasma membrane (Fig. 4C) (163, 185), 
suggesting that this G2 myristoylation site is not essential for membrane targeting, but 
may be involved in the SSP-GP2 interaction in order to mediate proper membrane fusion.  
Consistent with previous studies (163, 166), the N20A mutation reduces the membrane 
fusion activity by ~ 75% (Fig. 5B). N20 residue is located within the SSP transmembrane 
domain 1 (TM1), which has been suggested to directly interact with the GP2 TM domain 
to affect GPC-mediated membrane fusion (166). The reduced fusion activity of the N20A 
mutation does not significantly affect VLP-mediated cell entry (Fig. 5B) or viral growth 
in vitro (Fig. 7B), but markedly reduces viral virulence in vivo (Fig. 8), suggesting that a 
suboptimal membrane fusion activity could have a major impact on viral infection in 
vivo.  
The N37A and R55A mutations do not reduce the membrane fusion activity (Fig. 5B) but 
rather appear to increase the levels of VLP-mediated cell entry efficacy (Fig. 8B). While 
these mutant viruses grow similarly as the WT virus in cell culture (Fig. 7B),  they 
showed reduced degrees of virulence in vivo (Fig. 8A-B). It is possible that the 
seemingly insignificant effects observed in cell culturing conditions can sometimes be 
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amplified in vivo. The exact molecular mechanism(s) by which N37 and R55 contribute 
to viral infectivity in vivo remains to be determined, but they do not seem to participate 
in the membrane fusion and/or cell entry. 
Materials and Methods 
Cell lines: 293T cells, BHK21, and A549 cells were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS, Sigma) and 
50 mg penicillin and streptomycin. BSRT7-5 cells, which stably express the T7 RNA 
polymerase, were obtained from K. Conzelmann (Ludwig-Maximilians-Universitӓt, 
Germany) and cultured in DMEM supplemented with 10% fetal bovine serum (FBS), 1 
mg Geneticin per ml, and 50 mg penicillin and streptomycin per ml. Vero cells were 
maintained in Eagle’s medium (MEM) with 10% FBS plus 50 mg penicillin and 
streptomycin per ml. 
Plasmids and transfection methods: Mutations in the SSP gene were created in the 
pCAGGS-PICV-GPC plasmid by overlapping PCR mutagenesis reactions, and the 
mutations were confirmed by sequencing. Plasmids used to rescue the PICV SSP mutant 
viruses have previously been described (146). A plasmid that contains the T7 promoter-
directed firefly luciferase gene has been obtained from J. Nunberg (University of 
Montana, USA). Plasmid transfection into 293T cells was performed by using the 
calcium phosphate method (187). Plasmid transfection into BSRT7-5 cells was 
performed by using the Lipofectamine2000 reagent as per the manufacturer’s protocol 
(Invitrogen).  
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Western blot: 293T cells were lysed at 48 hrs post transfection by lysis buffer (50 mM 
Tris-HCl, 150 mM NaCl, 1% NP40, pH=7.4) with protease inhibitor cocktail (Roche). 
Lysates were assayed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and 
transferred to nitrocellulose membranes (NC membrane). NC membrane was blocked 
with 5% non-fat powdered milk in Tris-HCl buffer (TBS) for 1 hr at room temperature. 
The membrane was incubated with anti-PICV guinea pig serum at 4 °C overnight, and 
washed three times with TBS (50 mM Tris-HCl, pH=7.4) and probed with IRDye 
800CW labeled donkey anti-guinea pig antibody and assayed by Odyssey infrared 
imaging system (LI-COR® Biosciences). 
Fusion assay: For eGFP syncytia formation assay, 293T cells were transfected with the 
eGFP plasmid together with the pCAGGS vector or individual GPC construct. 36 hrs 
post-transfection, cells were treated with pH-adjusted medium (pH=5) for 5 mins and 
then replaced with fresh complete DMEM medium for additional 12 hrs of culturing. The 
cell cultures were visualized by fluorescence microscopy. 
For luciferase-based fusion assay, 293T cells were transfected with the T7-promoter-
driven firefly luciferase reporter plasmid together with either pCAGGS empty vector or 
individual GPC construct. 24 hrs post-transfection, the transfected 293T cells were 
detached by trypsinization, mixed with BSR-T7 cells that constitutively express T7 RNA 
polymerase. At 36 hrs post-transfection, cells were treated with pH-adjusted medium 
(pH=5) for 5 mins and then replaced with fresh complete DMEM medium for additional 
12 hrs of culturing. Cells were lysed 12 hrs later and analyzed by the luciferase assay kit 
(Promega). 
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Cell surface expression of the GPC complex: 293T cells were transfected with either 
pCAGGS empty vector or individual GPC construct. 48 hrs post-transfection, cells were 
fixed with 4% PFA for 5 min, washed once with PBS, and blocked with 1% bovine 
serum albumin (BSA) for 1 hr at 4 °C. Cells were then incubated with guinea pig anti-
PICV serum overnight at 4 °C, washed with PBS three times, and incubated with Alexa 
Fluor® 488- labeled goat anti-guinea pig antibody for 1 hrs at ambient temperature. Cells 
were washed three times with PBS and analyzed for GPC-positive cells by flow 
cytometry. 
GPC-pseudotyped lentivirus-like particles (VLP) and cell entry assay. As described 
previously (107), 293T cells were transfected with three plasmids, pCMVRΔ8.91, a 
plasmid containing the HIV genome except for the packaging signal and envelope gene; 
pHR’GFP, a plasmid containing a GFP expression cassette and HIV packaging signal; 
and a pCAGGS expression vector expressing either WT PICV GPC or SSP mutant, using 
the Lipofectamine2000 (Invitrogen) transfection reagent. Supernatants of the transfected 
cells were collected at different time points up to 96 hrs post-transfection and filtered 
through a 0.45 µm filter. After purification through sucrose gradient ultracentrifugation, 
the pseudotyped VLPs were resuspended in DMEM, aliquoted, and stored at -80oC. The 
amount of VLPs was normalized by the HIV-1 p24 levels as determined by Western blot 
analysis using an anti-HIV-1 p24 antibody, which is kindly provided by E. Hunter 
(Emory University). For cell entry assay, respective GPC-pseudotyped VLPs were used 
to transduce 293T cells in the presence of polybrene at 8 μg/ml.  24 hrs post-transduction, 
GFP-positive cells were analyzed by flow cytometry. 
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Generation of recombinant PICV mutants and viral growth curve analysis: WT and 
SSP mutant viruses were rescued as previously described (146). The L plasmid together 
with the S plasmid containing either WT or mutant SSP was transfected into BSRT7-5 
cells.  At various time points post-transfection, virus supernatants were collected for 
plaque assaying to determine whether any infectious virus particles were generated. 
Individual plaques were then picked and amplified once in BHK-21 cells to prepare virus 
stocks. Each viral mutant was confirmed by sequence analysis after RT-PCR. For viral 
growth curve analysis, BHK-21 cells were infected with either WT or mutant virus at 
MOI of 0.01, each in triplicates. At different time points post infection, supernatants were 
collected and analyzed for infectious viral particles by plaque assaying in Vero cells as 
previously described (173). 
Animal experiments.  Outbred male Hartley guinea pigs of 350-400g were purchased 
from Charles River laboratories and acclimatized for 3 days before experiments.  
Animals were administrated intraperitoneally (i.p.) with PBS or 10,000 PFU of respective 
virus.  Body weights and rectal temperatures were monitored daily for up to 18 days. 
Animals were defined as having reached terminal points either when their body weight 
decreased by >30% as compared to a nomogram or if the rectal temperature fell below 38 
°C in addition to body weight loss.  Statistical analyses of the survival curves were 
performed using the Log-rank (Mantel-Cox) χ2 Test using GraphPad Prism 5 software.  
The statistical significance of duration-of-fever was analyzed using the student “t” test.   
This work has been published in the Journal of Virology (J Virol. 2016 Oct 
28;90(22):10390-10397) 
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Chapter III 
Functional Analysis of the Conserved Amino Acids of Arenaviral Glycoprotein GP2 
C-terminal Domain 
Introduction 
Several arenaviruses cause human hemorrhagic fever diseases, for which preventive or 
therapeutic measures are limited(188-191). Lassa virus (LASV) causes Lassa fever in 
West Africa with 300,000 to 500,000 infection cases and ~5,000 deaths annually(158). 
Junin virus (JUNV) is endemic in South America and causes Argentine hemorrhagic 
fever. Candid#1 is the only vaccine to prevent JUNV infections and can only be used in 
Argentina.  Except for Candid#1, there is no vaccine for any other arenaviruses (192). 
Ribavirin is used to treat arenaviral hemorrhagic fever diseases but it only shows some 
efficacy when it is administered at the early stage of the infection(159). Supportive care 
is the main treatment for arenaviral hemorrhagic fevers(193). Therefore, effective 
vaccines and antiviral agents are urgently needed. 
Arenavirus is an enveloped ambisense RNA virus(194). Arenaviral genome contains two 
RNA segments, the large segment (L seg) and small segment (S seg). The L seg encodes 
viral RNA-dependent RNA polymerase and the viral matrix protein Z. The S seg encodes 
viral nucleoprotein (NP) and viral glycoprotein complex (GPC). Arenaviral glycoprotein 
is synthesized as a single polypeptide precursor which is posttranslationally processed 
into a stable signal peptide (SSP), receptor binding GP1 and transmembrane fusion 
peptide GP2. GP2 is a type I fusion peptide with its fusion domain located at the N 
terminal domain, which has been well studied (195, 196). The roles of GP2 C-terminal 
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domain (CTD) conserved residues in mediating cell entry have not been well understood. 
Previous studies have identified two zinc-binding domains located at JUNV GP2 CTD: 
H447, H449, C455, and H485 that formed the first zinc-binding domain, and H459, 
C467, C469 and C57 of SSP that formed the second zinc-binding domain (179, 184). 
Mutagenesis study of JUNV GP2 CTD showed that all GP2 CTD zinc-binding residues 
are essential for glycoprotein processing and GPC functions. The other conserved 
residues of GP2 CTD, R470, P478, P480, R482, W503, R505, and K508 have not been 
investigated and the roles of all these conserved amino acids at the CTD of GPC in 
authentic arenavirus life cycle have not yet been investigated.  
In this study, we characterized the roles of GP2 CTD conserved residues in GPC 
expression, processing, fusion activity and authentic arenaviral lifecycle by using the 
PICV reverse genetics system (146). Our data indicate that all of the zinc-binding 
residues, as well as the W503 residue in GP2 CTD, is essential for glycoprotein 
processing, fusion activity, and viral life cycle and that three residues, R470, P480, and 
R482, might play important roles in optimizing glycoprotein processing, GPC trafficking, 
and virus assembly in virus-infected cells. 
Results 
Effects of GP2 CTD mutations on glycoprotein expression and processing. 13 
residues of GP2 CTD are highly conserved among 22 different arenaviruses (Fig. 9A), 
We introduced alanine substitutions at each of these highly conserved residues H469, 
R470, H471, C477, P478, P480, H481, R482, C489, C491, W503, and G492 that is also 
highly conserved, as well as R505 and K508,  are less conserved, for which we 
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introduced a double mutation (R505A/K508A). To investigate whether these conserved 
residues affect glycoprotein complex (GPC) expression and processing, 2 µg of either 
empty, WT or GP2 CTD mutant plasmid (pCAGGS-GP) was transfected into 293T cells. 
48 h post transfection, the cells were lysed and analyzed by Western blot using guinea pig 
anti-PICV serum. The cleavage efficiency was calculated as the ratio of cleaved products 
to the total amount of proteins (processed and unprocessed glycoprotein). Mutants P478A 
and R505A/K508A showed similar cleavage efficiency levels to that of the WT, whereas 
all other mutants appeared to be defective at processing (Fig. 9B), indicating that 
residues, H469, R470, H471, C477, P480, H481, R482, C489, C491, and W503 are 
essential for GPC processing.  In particular, our data indicate that the zinc-binding 
residues, H469, H471, C477, H481, C489, and C491 completely impaired GPC 
processing. 
We next detected the levels of GPC cell surface and total expression to evaluate the GPC 
trafficking efficiency. 2 μg of either empty, WT or GP2 CTD mutant plasmid (pCAGGS-
GP) were transfected into 293T cells. 48 h post transfection, cells were analyzed by flow 
cytometry. Mutants P478A, R505A/K508A showed similar ratios of GPC surface 
expression positive cell numbers to total GPC expression positive cell numbers (Fig. 10A 
and 10B). Mutants H469A, P480A, and R482A showed ~30% lower ratios than WT (Fig. 
10A and 10B). All other mutants showed significantly lower ratios, ~70% lower than 
WT, suggesting that these residues, R470, H471, C477, H481, C489, C491, and W503 
are essential for GPC trafficking to the cell surface (Fig. 10A and 10B).  
Effects of GP2 CTD mutations on GPC mediated-membrane fusion activity. To  
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Fig. 9. 
 
Fig. 9. (A) Sequence alignment of arenavirus glycoprotein GP2 CTD regions. Conserved 
residues are indicated Red square. Abbreviations: MOBV, Mobala virus; IPPYV, Ippy 
virus; FLEV, Flexal virus; PARV, Parana virus; ALLV, Allpahuayo virus; PIRV, Pirital 
virus; TCRV, Tacaribe virus; CPXV, Cupixi virus; AMAV, Amapari virus; MACV, 
Machupo virus; GTOV, Guanarito virus; SABV, Sabia virus; LATV, Latino virus; 
WWAV, Whitewater Arroyo virus; TAMV, Tamiami virus; BCNV, Bear Canyon virus. (B) 
Expression and processing of wild-type (WT) and mutant PICV GPCs. Expression 
vectors of WT or GP2 CTD mutants (1 µg of plasmid DNA unless otherwise indicated) 
were transfected into 293T cells. Cell lysates were analyzed by Western blotting with 
guinea pig anti-PICV antisera. Actin expression was used to monitor equal sample 
loading efficiency. 
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Fig. 10. 
 
Fig. 10. Cell surface and total expression of WT and GP2 CTD mutant PICV GPCs. (A) 
Shown the averages deviations of GPC surface and total expression from three 
independent experiments. (B) shown the ratio of surface/total GPC expression. 
evaluate the effects of each GP2 mutation on the GPC mediated membrane fusion 
activity, we carried out a syncytium formation fusion assay. 1 µg of either empty, WT or 
each GP2 mutant plasmid together with eGFP expression plasmid were transfected into 
293T cells. 36 h post transfection, the cells were treated with low pH medium (pH=4.0) 
for 5 minutes and replaced with normal complete DMEM for continuing culture for 12 h. 
Then the cells were analyzed by fluorescence microscopy. WT, P478A, and 
R505A/K508A GPC expressions led to relatively efficient formations of syncytia (Fig. 
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11). However, we did not observe eGFP syncytia formations from the other GP2 CTD 
mutants transfected cells, suggesting the critical roles of H469, R470, H471, C477, P480, 




Fig. 11. Effects of GP2 CTD mutations on membrane-membrane fusion activity. Cells 
were transfected with a plasmid expressing eGFP together with either an empty vector 
(negative) or plasmids expressing WT or individual mutant PICV GPCs. Cells were 
treated with low-pH medium to trigger membrane fusion and monitored by fluorescence 
microscopy. 
Effects of GP2 CTD mutations on viral growth. To investigate the biological roles of 
GP2 CTD conserved residues in the arenaviral life cycle, we created the same series of 
individual alanine substitutions in the glycoprotein gene encoded on the small segment 
(S) of the PICV reverse genetics system. Either WT or the individual GP2 CTD mutated 
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S plasmid together with the large segment (L) containing plasmid were transfected into 
BSRT7-5 cells in order to rescue recombinant viruses. WT, R470A, P478A, P480A, 
R482A, and R505A/K508A mutants viruses were successfully rescued (Fig. 12A). 
However, we were not able to rescue viruses in cells transfected with plasmid 
combinations that carry the individual mutation H469A, H471A, C477A, H481A, 
C489A, C491A, and W503A on the GPC gene of S segment of the viral genome along 
with the L segment containing plasmid, despite repeated attempts, suggesting that the 
zinc-binding residues of GP2 CTD, H469, H471, C477, H481, C489, and C491, as well 
as the W503 residues, are essential for the PICV life cycle.  
To investigate the roles of the GP2 CTD mutants in viral growth kinetics, we infected the 
BHK21 cells with either WT or the individual GP2 CTD mutant (R470A, P478A, P480A, 
R482A, and R505A/K508A) at MOI=0.01 and collected the cellular supernatants 
containing viruses at 24 h, 48 h, 72 h, and 96 h postinfection in order to conduct plaque 
assaying on Vero cells. The results showed that the GP2 CTD mutants, P478A, P480A, 
R482A, and R505A/K508A showed WT-like growth kinetics, whereas the R470A mutant 
grew 1 log less than the WT, suggesting that R470 residue plays an important role in 
virus replication kinetics (Fig. 12B). Viruses from the supernatants used in the growth 
curve experiments were sequenced to validate the identity of each of the mutants and to 




















Fig. 12. GP2 CTD mutant viral kinetics. (A) The plaque size of individual GP2 CTD 
mutant viruses. (B) GP2 mutant viral growth curve. BHK21 cells were infected with 
either WT or GP2 CTD mutant at an MOI=0.01, the supernatants were collected at 
indicated time and virus titer was calculated by plaque assay in VERO cells. (C) 
Glycoprotein processing in the viruses infected cells and virions. For the Western blot for 
viruses infected cells, BKK21 cells were infected with indicated viruses at a MOI=0.1 
and the cells were collected at 48 hrs post-infection. For the Western blot for virions, 
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BHK21 cells were infected with indicated viruses at an MOI=0.01, supernatants were 
collected at 24h, 48h, and 72h post infection and concentrated by ultracentrifuge. The 
samples were analyzed by Western blot with guinea pig anti-PICV serum. 
Glycoprotein expression and processing in GP2 CTD mutant virus-infected cells 
and virions. It was somewhat unexpected that we could rescue the R470A, P480A, and 
R482A mutant viruses since no cell fusion activity was detected for any of these mutants 
in the plasmid transfected cells (Fig. 11). We, therefore, asked whether GPCs of these 
mutant viruses were processed in the infected cells and in the virions. To address this 
question, we infected the BHK21 cells at MOI=0.1 and collected the cell lysates at 48 h 
post infection. We also infected the BHK21 cells at MOI=0.1 and collected the 
supernatants at 24 h, 48 h, 72 h, and 96 h postinfection. The supernatants were then 
concentrated by ultracentrifuge at 27,000 rpm for 2 hrs. The cell lysates and virions were 
analyzed by Western blot using guinea pig anti-PICV serum. The results showed that all 
GPCs in both cell lysates and virions of these GP2 CTD mutant viruses, R470A, P480A, 
and R482A were properly processed (Fig. 12C). We also noticed that significantly higher 
levels of unprocessed GP1/GP2 remained in the R470A, P478A, P480A, and R482A 
mutant viruses infected cells compared to the WT and R505A/K508A mutant viruses 
infected cells, suggesting that R470, P478, P480, R482 residues indeed play important 
roles in glycoprotein trafficking/assembly and especially in glycoprotein processing in 
the authentic virus-infected cells. The markedly lower levels of processed GP1/GP2 
observed with the R470A mutant virus in the virion sample correlated well with its lower 
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virus titers and plaque sizes as compared to the WT and other GP2 mutant viruses (Fig. 
12B and 12A). 
Discussion 
In this study, we have determined the important roles of the conserved residues of GP2 
CTD of the PICV by using both plasmid overexpression system and the PICV reverse 
genetics system. In particular, our data indicate that the W503 and zinc-binding residues, 
H469, H471, C477, H481, C489, and C491 are essential for the PICV life cycle.  
The roles of H469, H471, C477, H481, C489, and C491 residues have previously been 
examined for the JUNV (179, 184). These residues formed two zinc-binding domains at 
the GP2 CTD. Further study on the second zinc domain of GP2 CTD has shown that GP2 
CTD forms an intersubunit zinc-binding center that incorporates Cys-57 of SSP, which 
might act to retain SSP in the GP-C complex and position the ectodomain loop of SSP for 
its role in modulating membrane fusion activity (184). Our results with PICV confirmed 
that all the zinc-binding residues are indeed essential for glycoprotein processing and 
GPC mediated membrane fusion activity (Fig. 9 and Fig. 11). Using the PICV reverse 
genetics system, we found that all the viruses carrying alanine substitutions in the zinc-
binding domain were not able to be rescued, which suggested that the zinc-binding 
domain at the GP2 CTD was also essential for PICV life cycle. 
Interestingly, we found that the R470 residue was required for glycoprotein processing 
and GPC mediated membrane fusion activity in cells overexpressing PICV GPC carrying 
this particular R470A mutation (Fig. 9 and Fig. 11). However, we were able to rescue 
virus carrying the R470A mutation, albeit the viral titer for this mutant virus was about 2-
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log lower than the WT PICV, and its growth kinetics were slower and its plaque size was 
significantly smaller than the WT virus (Fig. 12A and 12B). The Western blot analysis 
showed that GPC of the R470A mutant virus-infected cells was processed properly, but 
that its processed levels on the virion was much less than the WT level (Fig. 12C), 
corroborating with the slower growth kinetics and smaller plaque sizes of this particular 
mutant virus as compared to the WT or other GP2 mutant viruses (Fig. 12A and 12B). It 
is possible to speculate that viral proteins and/or cellular factors are involved in GPC 
processing and trafficking during the virus infection, which facilitates the GPC cell 
surface assembly to form virions.  
The virus carrying the P480A mutation was able to be rescued. This virus showed about 
1-log lower viral titers at 24h and 48 h compared to the WT. The plaque size seems to be 
relatively smaller than the WT. Higher levels of unprocessed GP1/GP2 products were 
observed as compared to that of the WT, suggesting that the P480 residue plays an 
important role in optimizing glycoprotein processing, GPC trafficking, and virus 
assembly. The same can be said about viruses that carry the P470A, P478A, or R482A 
substitution mutation (Fig. 12C). 
In summary, our data suggest that arenaviral GP2 CTD plays an essential role in 
glycoprotein processing, GPC mediated membrane-membrane fusion activity, optimizing 
GPC trafficking and virion particle formation. Knowledge obtained from this study may 
provide the structure-based targets of GP2 CTD for developing arenaviral therapeutics. 
Materials and Methods 
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Cell line. 293T and BSRT7-5 cells were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM, Sigma) plus 10% fetal bovine serum (FBS, Sigma) and 50 mg/ml 
penicillin and streptomycin (Invitrogen). Vero and BHK21 cells were maintained in 
Eagles’ medium (MEM, Invitrogen) with 10% FBS, 50 mg/ml penicillin and 
streptomycin.  
Plasmids and transfection methods. Mutations in the GP2 CTD gene of pUC18-Seg 
(plasmid for the PICV reverse genetic system) were created by rolling circle mutagenesis. 
Mutations in the GP2 CTD gene of pCAGGS-GP (plasmid for GPC overexpression in 
mammalian cells) were transferred from the plasmids of pUC18-Seg GP2 CTD mutants. 
Calcium phosphate method was used for 293T cells transfection. Lipofectamine 300 was 
used for BSRT7-5 cells transfection. 
Western blotting. 293T, BHK21 or concentrated virions were lysed by lysis buffer 
(50mM Tris-HCl, 150mM NaCl, 1% NP-40, pH7.4) with protease inhibitors (Roche). 
Lysates were assayed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and transferred to nitrocellulose membranes (NC membrane, Bio-Rad). 
The NC membrane was blocked with 5% nonfat powdered milk in Tris-HCl buffer (TBS, 
pH=7.4) for 1 h at room temperature and incubated with either guinea pig anti-PICV 
serum or anti-actin antibody (Sigma) at 4°C overnight. The next day, the NC membrane 
was washed by TBS for three times and incubated with either IRDye 800CW-labeled 
donkey anti-guinea antibody (LI-COR Biosciences) or HRP labeled goat anti-mouse 
antibody (PerkinElmer) for 1 h at RT. The NC membrane was washed with TBS for three 
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times and analyzed by either Odyssey infrared imaging system (LI-COR Biosciences) or 
MyECL imager system (ThermoFisher). 
Fusion Assay. Enhanced green fluorescent protein (eGFP) syncytium formation analysis 
was used to monitor the GPC induced fusion activity as previously described (197). 
Total and Cell surface expression of the GPC. For GPC cell surface expression level 
analysis, 293T cells were transfected with 2 µg of either empty, wild-type (WT) or GP2 
CTD mutation plasmid. 48 hrs post-transfection, the cells were trypsinized and fixed with 
4% PFA, cells were then blocked with blocking buffer (1%BSA, 1% normal goat serum, 
200mM glycine in PBS, pH=7.4) and stained with guinea pig anti-PICV serum and 
fluorescein isothiocyanate (FITC)-conjugated goat anti-guinea pig antibody. For the total 
GPC expression level analysis, the same procedure was carried out plus 0.1% saponin 
was added into blocking buffer and antibody solutions for permeabilization. 
Generation of recombinant PICV mutants and viral growth curve. WT and GP2 
CTD mutant viruses were rescued as previously described (197). Viral growth curve 
analysis was carried out on BHK21 cells as previously described (197). 
Glycoprotein expression and processing in virus-infected cells and virions. For the 
analysis of glycoprotein expression and processing in virus-infected cells, BHK21 cells 
were infected with either mock, WT or GP2 CTD mutants at MOI=0.1 for 24 h or 48 h. 
The cell lysates were analyzed by Western blot with guinea pig anti-PICV serum. For the 
analysis of glycoprotein expression and processing in various, BHK21 cells were infected 
with either mock, WT or GP2 CTD mutants at MOI=0.1 in 10 cm dishes, supernatants 
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were collected at 24 h, 48 h, 72 h post infection and concentrated by ultracentrifuge. The 
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Chapter IV 
Arenaviral Nucleoproteins Suppress PACT-induced Augmentation of RIG-I 
Function to Inhibit Type I Interferon Production 
Introduction 
Mammalian arenaviruses are phylogenetically, serologically and geographically divided 
into Old World (OW) and New World (NW) subgroups. Several members of the OW and 
NW-B viruses are known to cause diseases in humans. In addition to Lassa virus (LASV) 
that causes endemic hemorrhagic fever (HF) infections in West Africa, six other 
arenaviruses can cause sporadic HF outbreaks in South Africa or South America (156, 
157). No vaccine is available for arenavirus pathogens, except for Junín virus (JUNV) 
vaccine Candid#1, which is licensed for use only in Argentina and offers some cross-
protection for another NW arenavirus (Machupo MACV) but not against LASV (198). 
Therapeutic options are limited and depend mainly on supportive cares. Ribavirin, a 
nonspecific antiviral compound, has shown some efficacy only if it is administered at an 
early stage of viral infection when the symptoms are insidious (159). Severe and lethal 
Lassa HF infections are associated with a generalized immune suppression of the infected 
hosts, as characterized by the absence of early immune responses, delayed and low levels 
of neutralizing antibody production and T cell activation, the molecular mechanisms of 
which have only recently been investigated in some details (199). 
RIG-I is a major cytosolic sensor of many RNA viruses (200), including arenaviruses 
(201). RIG-I recognizes viral dsRNA carrying the 5’ triphosphate (202). Structural and 
biochemical studies from several laboratories have provided tantalizing evidence for a 
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multistep model of RIG-I activation via binding to dsRNA (200, 203). In uninfected cells, 
RIG-I is kept inactive by a closed conformation, in which its N-terminal CARD domains 
and C-terminal (repression) domain (CTD) are kept close to the centrally located helicase 
domain, in which specific Thr and Ser residues in the CTD and CARDs are 
phosphorylated by casein kinase II (CKII) and protein kinase C (PKC)-α/β, respectively 
(204-207). Upon viral infection, RIG-I binds to RNA ligand to facilitate its 
conformational changes, dimerization, and multimerization. A series of protein 
modifications (ubiquitylation and dephosphorylation) of RIG-I help mediate its 
conformational changes (205-213) and translocation to mitochondria-associated 
membranes (MAMs), where RIG-I interacts with MAVS to mediate several downstream 
processes in order to induce type I IFN production (214). ATP hydrolysis via the ATPase 
function of RIG-I has been shown to be critical for RIG-I activation (215), as RIG-I can 
translocate on the bound dsRNA in an ATP hydrolysis-driven manner (216, 217). 
A cellular factor known as PACT has been shown to greatly enhance RIG-I function by 
interacting with it (218). PACT is a 313-aa protein that contains 3 conserved dsRNA-
binding motifs (dsRBMs), with dsRBM1 and 2 binding to dsRNA and dsRBM3 
activating the dsRNA-dependent kinase PKR (219). PACT has been shown to activate 
RIG-I via interaction with the C-terminal repression domain of RIG-I and activation of 
the RIG-I’s ATPase function to potently enhance type I IFN production (218). The same 
study shows that the interaction between RIG-I and PACT can be detected endogenously 
in cells [upon Sendai virus (SeV) infection] and that the enforced expression of PACT 
alone has no effect on the IFNβ promoter activity, but when co-expressed with RIG-I 
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with a functional helicase activity, PACT can significantly augment RIG-I activation. 
PACT potentiates RIG-I function by activating the intrinsic ATPase activity of RIG-I at a 
level comparable to the preferred RIG-I ligand 5’-triphosphate dsRNA (218).  
For a wide range of human pathogenic viruses, such as Ebola (EBOV), influenza A virus 
(IAV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), human T-cell 
leukemia virus (HTLV1), mouse hepatitis virus (MHV), measles virus (MeV), and 
human simplex virus (HSV1), their viral proteins or defective interfering (DI) RNAs 
have been shown to modulate PACT-mediated enhancement of RIG-I’s function to drive 
the expression of type I IFN (218, 220-226). Specifically, the EBOV VP35, IAV NS1, 
HSV1 Us11, MERS-CoV 4a and nucleocapsid (N) proteins, as well as the N protein of 
MHV, have been shown to directly disrupt the interaction between RIG-I and PACT, and 
hence block the ability of PACT to activate RIG-I (218, 220-223, 226). We and other 
researchers have previously shown that arenaviral nucleoproteins (NPs) can efficiently 
suppress type I IFN production by degrading immunostimulatory RNAs via its intrinsic 
3’-5’ exoribonuclease activity (126, 227-233).  In the current study, we show that LASV 
NP could effectively block PACT-induced augmentation of RIG-I function and therefore 
suppressed type I IFN production.  We also show that the LASV NP RNase activity is 
required for inhibition of PACT-induced potentiation of RIG-I function and therefore 
plays an essential role for arenavirus replication in interferon-competent cells by limiting 
the functions of PACT and RIG-I. 
Results 
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Arenaviral nucleoproteins (NPs) blocked PACT-augmented RIG-I-induced IFNβ 
production. 
Previous studies have shown that PACT can strongly augment RIG-I-induced activation 
of the IFNβ promoter (218). To determine whether arenaviral NPs could suppress PACT- 
and RIG-I-induced IFNβ activation, we conducted the IFNβ promoter-dependent 
luciferase (LUC) assay.  293T cells were transfected with either an empty vector or a 
plasmid expressing the WT Lassa virus (LASV) NP gene together with the IFNβ -LUC 
reporter plasmid, β-gal expressing plasmid (as transfection efficiency control), RIG-I-
expression plasmid, and/or PACT expression plasmid. The results showed that RIG-I 
alone activated the IFNβ promoter activity by 60-fold, and together with PACT, strongly 
activated the IFNβ promoter activity by 240-fold (Fig. 13A), confirming previous studies 
that PACT can potently enhance RIG-I induced IFNβ production. The inclusion of LASV 
NP largely suppressed the IFNβ activation induced by either RIG-I or RIG-I/PACT 
combination. Our data suggest that LASV NP can suppress both RIG-I alone and RIG-
I/PACT induced IFNβ activation. 
We next asked whether this inhibition was applicable to other arenaviral NPs. Using a 
similar set up as described in Figure 1A, we examined the impact of NPs from LASV, 
Junín virus (JUNV), Machupo virus (MACV), Pichinde virus (PICV), and Tacaribe virus 
(TCRV) on RIG-I or RIG-I/PACT induced IFNβ-promoter activation. The results showed 
that all arenaviral NPs were able to suppress PACT/RIG-I-induced IFNβ-promoter 
activation to similar levels (Fig. 13B), suggesting that this is a general mechanism of 
innate immune suppression by arenaviral NPs.  
  64 
Fig. 13 
 
Fig. 13. 293T cells were transfected with the indicated plasmids together with IFNβ 
promoter-directed luciferase (LUC) plasmid and β-gal plasmid for normalization of 
transfection efficiency. (A) LASV NP could inhibit both RIG-I and RIG-I plus PACT 
induced IFNβ promoter activity. (B) LASV NP, JUNV NP, MACV NP, TCRV NP and 
PICV NP could inhibit RIG-I and PACT induced IFNβ promoter activity. (C) WT LASV 
NP, WT LASV NP C-terminal RNase-containing domain (NP-C), but not RNase-defective 
NP (NP mut) or NP N-terminal domain (NP-N), could inhibit RIG-I and PACT induced 
IFNβ promoter activity. The experiments that generated data for each of the panels 
shown had been repeated three times. The results shown are the average of one such 
experiment (in triplicates). The luciferase (LUC) activities of certain samples were 
compared to the corresponding controls by the Student’s t-test, ***, P<0.01. The western 
blots shown below the bar graphs confirmed the expression of the transgenes (FLAG-
RIG-I, HA-PACT, and NP) as well as of the housekeeping GAPDH gene using the 
appropriate antibodies. 
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The 3’-5’ exoribonuclease (RNase) function of NPs was required for inhibition of 
PACT/RIG-I-induced IFNβ-promoter activation. 
We and other researchers have shown that the NP RNase activity was required for its 
inhibition of type I IFN production (126, 227-233). To determine whether NP’s RNase 
activity was also necessary to inhibit PACT- and RIG-I-induced IFNβ promoter 
activities, plasmids carrying either the WT LASV NP, LASV NP with a known RNase-
defective mutation (D389A) (126, 228), the C-terminal RNase-containing LASV NP 
(126), or its N terminal domain without enzymatic function was individually transfected 
into 293T cells with the IFNβ-LUC and β-gal expressing plasmids along with the RIG-I-
expressing and PACT-expressing plasmids. The results showed that RNase-containing 
LASV NP and its C terminal domain strongly suppressed PACT- and RIG-I-induced 
IFNβ promoter activation, but the RNase-defective D389A mutant and the N-terminal 
non-RNase containing domain of NP did not exhibit such an inhibitory effect (Fig. 13C). 
The NP D389A RNase-defective mutant appeared to consistently further enhance the 
levels of RIG-I activation (after repeated assaying), the molecular mechanism of which is 
not known. These data demonstrate that NP’s RNase activity is required for NP inhibition 
of PACT- and RIG-I-induced IFNβ promoter activities. 
NP-mediated inhibition of PACT/RIG-I was not via disruption of PACT and RIG-I 
interaction. 
Recent studies have shown that several viral proteins, such as the EBOV VP35, HSV 
Us11, and IAV NS1 protein, can suppress PACT- and RIG-I-induced IFNβ activities by 
disrupting the protein-protein interactions between RIG-I and PACT (220-223, 226). We 
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wondered whether arenaviral NPs could also suppress PACT- and RIG-I-induced IFNβ 
promoter activity through a similar mechanism. Since WT NP but not the RNase-
deficient NP could suppress the IFNβ promoter, we asked whether there was any 
difference between WT LASV NP and D389A RNase-defective NP in their interactions 
with RIG-I and/or PACT. We performed co-immunoprecipitation assays to analyze the 
interactions among NP, RIG-I, and PACT in lysates of 293T cells transfected with 
plasmids expressing HA-PACT and FLAG-RIG-I along with a plasmid expressing either 
the wild-type NP (WT NP-myc) or the RNase-defective NP mutant (NP mut-myc) or an 
empty plasmid control. Immunoprecipitation (IP) with an anti-HA antibody but not with 
an anti-IgG control antibody could pull down FLAG-RIG-I (Fig. 14A, compare lanes 2, 
5, 8 to lanes 3, 6, 9), demonstrating the specific interaction between FLAG-RIG-I and 
HA-PACT by immunoblotting (IB), which is consistent with a previous study (218) . The 
immunoprecipitates also contained similar levels of WT and mutant NP when the 
respective NP plasmid was co-transfected (Fig. 14A, lanes 6 and 9, protein bands shown 
as NP-myc), suggesting that both WT and mutant NP can interact with PACT. 
Furthermore, the presence of WT or mutant NP reduced but did not completely eliminate 
the FLAG-RIG-I protein levels in the immunoprecipitates (Fig. 14A, compare FLAG-
RIG-I levels in lanes 6 and 9 to lane 3), which was partly due to the decreased total RIG-I 
expression levels in these cell lysates (Fig. 14A, compare the FLAG-RIG-I levels of the 
cellular lysates shown in lanes 1, 4 and 7). Nevertheless, there appeared to be no major 
differences between WT and NP mut in disrupting the RIG-I/PACT interactions  (Fig. 
14A, compare FLAG-RIG-I levels in lanes 6 and 9), indicating that the NP-mediated 
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PACT/RIG-I inhibition is not mediated mainly through the abolishment of the PACT-
RIG-I interaction, as has previously been demonstrated for other viral proteins (220-223, 
226). To address the interaction between PACT and NP in authentic virus infection, we 
infected HEK293 cells with WT PICV, performed IP assays of the infected cell lysates 
with an anti-IgG control antibody or an anti-PACT antibody followed by immunoblotting 
(IB) with either an anti-NP antibody or an anti-PACT antibody. PICV NP was readily 
detected in the immunoprecipitates pulled down with an anti-PACT antibody but not with 
an anti-IgG control (Fig. 14B), demonstrating the interaction of PICV NP with 
endogenous PACT during viral infection. 
Fig. 14. 
 
Fig. 14. LASV NP interacts with the RIG-I/PACT complex. (A) 293T cells were 
transfected with the indicated plasmids shown in the bottom of the gels. 48 hrs post-
transfection, cell lysates were immunoprecipitated (IP) with either anti-IgG or anti-HA 
antibody and analyzed by immunoblotting (IB) with anti-FLAG, anti-myc, or anti-HA 
antibody. (B) HEK293 cells were infected with WT PICV for 24 hrs. Cell lysates were 
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pulled down with either anti-IgG or anti-PACT antibody and analyzed by immunoblotting 
(IB) with antibodies against NP or PACT. 
RIG-I and PACT played important roles in restriction of Pichinde virus (PICV) 
replication. 
To understand the roles of RIG-I, PACT and NP in authentic arenavirus infection, we 
characterized the growth kinetics of recombinant WT and RNase-defective PICV 
generated from reverse genetics system (173, 231) in normal (WT), RIG-I knockout (KO) 
or PACT KO mouse embryonic fibroblast (MEF) cells (234, 235).  We separately 
infected these cells with either recombinant WT PICV or the RNase-defective D389A 
PICV at the multiplicity of infection (MOI) of 0.01. Cellular supernatants were collected 
at 24 h, 48 h, 72 h and 96 h post infection. The results showed that the WT PICV could 
replicate in both RIG-I KO and PACT KO cells at levels that were significantly higher 
than in the WT MEF cells (Fig. 15A, 15B), strongly suggesting that these cellular 
proteins can restrict PICV replication. While the RNase-defective D389A PICV could 
barely grow in WT MEF cells, it grew to a similar level as that of the WT PICV in the 
RIG-I KO MEF cells (Fig. 15A). It also grew relatively better in the PACT KO MEF 
cells than in WT MEF cells, but to a level that was less than in the RIG-I KO MEF cells 
(Fig. 15A, 15B).  Collectively, these data indicate that both RIG-I and PACT restrict 
PICV replication and that the viral NP RNase function potently antagonizes these host 
restriction factors in order to optimize virus replication.  These data also implicate RIG-I 
as a sensor for arenavirus, and PACT plays an enhancing role of host innate immune 
response to arenavirus infection. 
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Although the PICV growth kinetics in RIG-I and PACT KO MEFs (Fig. 15A and 15B) 
are consistent with the role of NP RNase activity in the inhibition of RIG-I/PACT 
signaling, the studies described in Figure 1 and Figure 2 were conducted in human cells 
with human RIG-I and human PACT proteins. While the human and mouse PACT 
proteins are highly conserved (>98%), the RIG-I proteins from both species show a 
higher degree of primary sequence variation (59.5% sequence conservation). We 
therefore decided to use human PACT and mouse RIG-I (mRIG-I) in a similar IFNβ-
LUC assay in an attempt to confirm the role of NP RNase activity in the suppression of 
PACT-enhanced mRIG-I-dependent IFNβ activation. Similar to the results shown in 
Figure 1C, WT NP but not RNase-defective NP, strongly suppressed mRIG-I/PACT-
induced IFNβ-promoter activation (Fig. 15C), suggesting that NP RNase activity plays a 
similar role to suppress both human and mouse RIG-I’s via the highly conserved PACT 
proteins, validating our choice of using MEFs for further analyses. Our data also 
demonstrate that mouse RIG-I and human RIG-I proteins are functionally 
interchangeable and are similarly impacted by the viral NP-mediated inhibition (Fig. 15A 
and Fig. 15C). These data are consistent with the viral growth kinetics in the RIG-I and 






  70 
Fig. 15 
 
Fig. 15. Viral growth kinetics of WT and mutant PICV in RIG-I KO (A) and PACT KO 
(B) mouse embryonic fibroblast (MEF) cells. Cells were infected with either WT or NP 
RNase-defective PICV mutant (PICV mut) at moi of 0.01. At different time points post 
infection, virus titers in the supernatants were quantified by plaque assay. WT cells are 
shown in red lines, whereas KO cells are shown in blue lines. WT PICV is shown in solid 
line, while mutant PICV is shown in dashed line. The experiments that generated data for 
each of the panels shown had been repeated three times. The results shown are the 
average of one such experiment (in triplicates). Titer of each type of virus samples from 
the KO MEF cells was compared to WT MEF cells by the Student’s t-test, ***, P<0.01, 
*, P<0.05. (C) WT LASV NP, but not RNase-defective NP (NP mut), could inhibit mouse 
RIG-I (mRIG-I)/PACT-induced IFNβ promoter activity. The experiments that generated 
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data for this panel had been repeated three times. The results shown are the average of 
one such experiment (in triplicates). The luciferase (LUC) activities of certain samples 
were compared to the corresponding controls by the Student’s t-test, ***, P<0.01. 
Expression of mRIG-I, PACT, NP, and housekeeping gene GAPDH in each transfection 
was detected by Western blotting with respective antibodies and shown at the bottom. 
WT and NP RNase-defective PICV infections induced differential IFNβ production 
in WT, RIG-I KO and PACT KO MEF cells. 
We next asked whether the different viral growth kinetics seen in cell cultures would 
correspond to the different levels of innate-immune gene expressions. To do this, we 
infected WT, RIG-I KO and PACT KO MEF cells with WT or NP RNase defective 
D389A PICV at different MOIs (MOI = 0.1, 1.0, and 5.0). The expression levels of the 
IFNβ, NFκB, ISG56, and IFNβ genes were quantified by either ELISA (Fig. 16) or 
quantitative RT-PCR (Fig. 17). The results showed that WT PICV effectively suppressed 
IFNβ expression in all cell lines tested (Fig. 16 and Fig. 17A). On a contrary, the RNase-
defective PICV induced significantly higher levels of IFNβ production as compared to 
the WT PICV virus in all cell lines tested (Fig. 16 and Fig. 17A). Significantly higher 
levels of NFκB and ISG56 mRNA levels were also detected in WT MEF cells infected 
with the NP RNase-defective PICV when compared to WT PICV infection (Fig. 17B and 
17C).  While there were no obvious IFNβ, NFκB and ISG56 expressions in the RIG-I KO 
MEFs when they were infected with either the WT or the NP RNase-defective PICV 
(Fig. 16, Fig. 17A, 17B and 17C), these mRNA levels were significantly induced in the 
PACT KO MEF cells when they were infected with the NP RNase-defective PICV (Fig. 
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17A, 17B, and 17C) but were still lower than those in WT MEF cells infected with the 
same NP RNase-defective PICV.  These data once again implicate that RIG-I acts as a 
major sensor of arenavirus, whereas PACT plays an enhancing role of host innate 
immune response to arenavirus infection. 
Fig. 16 
 
Fig. 16. IFNβ expression levels from different types of MEF cells stimulated by either WT 
or RNase defective PICV (NP mut) infection (MOI=1 or MOI=0.1). (A) IFNβ expression 
levels measured by ELISA. The experiments that produced data for this graph had been 
repeated three times. The results shown are the average of one such experiment (in 
triplicates). The IFNβ expression levels for certain samples were compared by Student t-
test, ***, P<0.01. 
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Fig. 17 
 
Fig. 17. IFNβ, NFκB and ISG56 mRNA levels from different types of MEF cells 
stimulated by infection with either WT or RNase defective PICV (NP mut) (MOI=5). The 
levels of the IFNβ and NFκB mRNA transcripts were measured at 16 hrs postinfection, 
whereas the levels of the ISG56 mRNA transcripts was measured at 4 hrs post infection. 
The house-keeping gene (GAPDH) mRNA levels were also measured to normalize the CT 
values. Experiments that generated data for each of the panels were repeated at least 3 
times. The mRNA levels of certain samples were compared by Student t-test, ***, 
P<0.01, *, P<0.05. 
Discussion 
In this study, we show for the first time that arenavirus NPs can strongly inhibit the RIG-
I/PACT activation through its RNase activity and that this inhibition is essential for viral 
replication in immune-competent cells.   
RIG-I is a major cytosolic sensor of RNA viruses that activate the early antiviral 
responses including the expression of the type I IFN. Recent studies have identified 
PACT as a positive regulator of the RIG-I signaling (218). PACT can strongly augment 
RIG-I’s function to activate type I IFN production through a direct protein-protein 
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interaction with RIG-I to stimulate RIG-I’s ATPase activity (218). Several viral 
antagonists, such as EBOV VP35, IAV NS1, HSV1 Us11, and MERS-CoV 4a and N 
proteins, and MHV N, have been shown to inhibit the PACT-enhanced RIG-I activation 
by directly disrupting the RIG-I-PACT interaction (220-223, 226). We show here that 
arenavirus NP can also effectively inhibit the PACT-enhanced RIG-I activation, but that 
its inhibitory mechanism is not through disrupting the RIG-I-PACT interaction. It is 
rather dependent on the NP’s RNase domain and function (Fig. 14), possibly by 
degrading the RNA ligands of the RIG-I/PACT complex. 
Our study suggests an essential role of RNA ligands in the PACT-enhanced RIG-I 
activation. RIG-I is known to recognize short dsRNA with a 5’-di/triphosphate end (215, 
236, 237). Although PACT is a dsRNA-binding protein (219), its physiological ligands 
and their functional role remain uncharacterized. Previous studies have mostly focused on 
the direct RIG-I-PACT protein-protein interactions in the activation of RIG-I function 
(218, 220-223, 226). In particular, when RIG-I and PACT are overexpressed in cells in 
the absence of viral infections or PAMP RNA transfection, it is generally assumed that 
PACT can directly activate RIG-I through direct protein-protein interaction. Our data on 
the NP RNase-dependent inhibition of PACT/RIG-I-induced IFNβ production (Fig. 13C) 
indicate that, even in cell over-expressing PACT and RIG-I without presence of PAMP 
RNAs, RNA ligands might still be essential for the PACT/RIG-I activation as targeting 
these RNA ligands by NP RNase effectively inhibits the PACT/RIG-I-induced IFNβ 
production. The identity of these RNA ligands is unknown but can be originated from 
both endogenous cellular RNAs (e.g., in the absence of viral infection or PAMP RNA 
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transfection) and exogenous PAMP RNAs (e.g., in virus-infected cells).  It is also 
unknown whether they are ligands for RIG-I or PACT or both. A recent study by Ho and 
colleagues shows that a defective interfering (DI) RNA from measles virus vaccine 
strongly activates IFNβ production through PACT and RIG-I and that this DI RNA is 
associated with PACT, implicating PACT as another cytoplasmic PAMP RNA sensor. 
Further studies are necessary to identify the endogenous and exogenous RNA ligands of 
PACT and RIG-I in order to fully understand the activation mechanism of the 
PACT/RIG-I complex. 
Both PAMP RNA and PACT can activate RIG-I ATPase activity, which is essential for 
RIG-I function, however, the exact role of ATPase of RIG-I has not been well 
characterized (217, 238, 239). Several studies have shown that RIG-I ATPase is involved 
in the discrimination of self-RNA versus nonself-RNA (238, 239), whereas other studies 
have shown that ATP hydrolysis is critical for RIG-I activation (215) to mediate its 
translocation on the bound dsRNA (216, 217). Our data show that RNA ligands (self 
and/or PAMP RNA) are essential for the PACT/RIG-I activation and that NP RNase 
activity can degrade these RNA ligands and therefore effectively inhibits the PACT/RIG-
I pathway. While we have not formally ruled out the involvement of RIG-I’s ATPase 
function, our data collectively indicate that NP mainly affects IFNβ production by 
degrading the RNA ligands to suppress the PACT/RIG-I pathway. 
Our study further demonstrates the restrictive roles of RIG-I and PACT in arenavirus 
replication. Previous studies have shown that RIG-I is a sensor of arenavirus infections 
(201). By recognizing the 5’ di/triphosphated dsRNA ligands derived from RNA virus 
  76 
replication, RIG-I recruits the adaptor protein MAVS to activate the downstream protein 
kinase complexes leading to the activation of several transcriptional factors such as IRF3 
and IRF7 that induce the production of type I IFNs and other antiviral genes to restrict 
viral replication at multiple steps (240-243). As a positive regulator of RIG-I, the 
functional role of PACT in authentic viral infection, however, is less clear. Previous 
studies have shown that the IFNβ production is attenuated in the PACT KO cells upon 
HSV or SeV infection (218, 223), suggesting that PACT plays an important role in IFNβ 
production upon virus infection. However, no prior studies have addressed whether 
PACT restricts virus replication. Our study has demonstrated for the first time that both 
RIG-I and PACT function to restrict arenavirus replication (Fig. 15). On the other hand, 
arenavirus utilizes its NP protein to effectively evade the PACT- and RIG-I-mediated 
inhibition via its RNase activity, allowing the virus to replicate at high levels in the 
infected cells. Recombinant PICV with an RNase-defective NP mutation completely lost 
the ability to grow in WT mouse embryonic cells (Fig. 15), consistent with our previous 
study in human lung epithelial A549 cells (231), demonstrating again that NP RNase-
mediated immune evasion is essential for arenavirus replication. This NP RNase-
defective mutant virus grows to a much higher level in the RIG-I-KO than in the PACT-
KO cells, indicating that RIG-I is the major target of the NP RNase-mediated inhibition 
during viral infection, consistent with an earlier finding (201). 
In summary, our study provides important insight into the role of PACT-enhanced RIG-I 
activation mechanism, reveals the functions of PACT and RIG-I as restriction factors of 
arenavirus infection, and demonstrates the essential role of the NP RNase-mediated 
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PACT/RIG-I inhibition. This new knowledge can be exploited for the development of 
novel antiviral treatments and/or vaccine development against some arenaviruses that can 
cause severe and lethal hemorrhagic fever diseases in humans.  
Materials and Methods 
Plasmids and cells: The LASV, JUNV, MACV, Tacaribe virus (TCRV) and Pichinde 
virus (PICV) NP genes were cloned into mammalian expression plasmid pCAGGS, 
respectively, with a C-terminal myc tag, except for PICV NP, which did not have a myc 
tag. Human RIG-I and PACT expression plasmids were kind gifts of C. Basler (Georgia 
State University) and G. Amarasinghe (Washington University), respectively. Mouse 
RIG-I expression plasmid was a kind gift of Dr. Adolfo Garcia-Sastre (Mount Sinai 
School of Medicine). Single alanine substitution of a conserved RNase catalytic residue 
(D389A) of the LASV NP protein was generated as described previously (228). Human 
kidney epithelial cells (293T and 293 cells) and baby hamster kidney cells (BHK21 and 
BSRT7-5 cells) were grown in Dulbecco’s modified Eagle’s medium (DMEM, Sigma) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS, Sigma) and 50 μg/ml 
penicillin-streptomycin. Vero cells were grown in minimum essential medium (MEM, 
Invitrogen) supplemented with 10% heat-inactivated FBS and 50 μg/ml penicillin-
streptomycin. RIG-I KO MEF cells and PACT KO MEF cells (derived from the C57BL/6 
mouse strain) were kind gifts of G. Sen (Cleveland Clinic) (234) and M. Gale, Jr. 
(University of Washington) (235), and were grown in DMEM supplemented with 10% 
heat-inactivated FBS and 50 μg/ml penicillin-streptomycin. 
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Generation of recombinant PICV mutants and viral growth curve analysis: The 
methods for generating the WT and NP RNase-deficient PICV have been described 
previously (231). Viral growth curve was carried out as previously described (197). 
PICV plaque assay: Vero cells were seeded into six-well plates at 50%-70% confluence 
and infected with 1 ml of serial 10-fold dilutions of viruses in MEM for 1 h at 37°C. 
After removal of the medium and washed with phosphate buffer saline (PBS), the cells 
were incubated in complete fresh MEM supplemented with 0.5% agar and cultured for 
additional 4 days at 37°C with 5% CO2. Plaques were stained overnight with a diluted 
neutral red solution (0.01%) in 0.5% agar–MEM–2% FBS medium. 
Coimmunoprecipitation assay: 293T cells were grown overnight to 60%-80% 
confluence in 10-cm tissue-culture dishes in complete DMEM supplemented with 1% 
penicillin-streptomycin and 10% FBS. Using a standard calcium phosphate transfection 
method, cells were transfected with 10 µg of each of the plasmids expressing the RIG-I 
and PACT along with 10 µg of wild-type (WT) LASV NP or 10 µg of NP RNase-
catalytic mutants (D389A). In a control experiment, 10 µg of an empty pCAGGS plasmid 
was used in place of the NP-expressing plasmid.  Forty-eight hours post-transfection, 
cells were lysed in lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, and 
protein inhibitor cocktail (Roche]). The cell lysates were incubated either with 1 µg of 
anti-HA or mouse IgG (Genescript), as a negative control, at 4°C for 2 h to 4 h, with 
constant rotation. Protein A/G beads (Santa Cruz) were added, and the samples were 
incubated with constant rotation at 4°C overnight. The protein complexes were washed 5 
times with lysis buffer, standard 2X Laemmli sample buffer was added, and the samples 
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were boiled for 5 min and then loaded onto an SDS-PAGE gel for Western blotting using 
a mouse anti-FLAG, anti-HA or anti-myc monoclonal antibody (Sigma). For the 
endogenous NP and PACT co-immunoprecipitation assay, 293 cells were seeded in 10 
cm dish with 60%-80% confluence for PICV infection. Twenty-four hours post infection, 
a similar co-IP assay was carried out with 1 µg of anti-PACT antibody (Cell Signaling 
Technology) and analyzed with the PACT- or NP-specific antibody as previously 
described (228). 
IFNβ promoter-dependent LUC assay: 293T cells were transfected with either an 
empty vector or the NP expression vector together with 100 ng of IFNβ-LUC reporter 
plasmid, which expresses the firefly luciferase (Fluc) reporter gene from the IFNβ 
promoter, and 50 ng of β-gal expressing plasmid for the purpose of transfection 
efficiency normalization. For RIG-I or RIG-I plus PACT mediated IFNβ  induction, 100 
ng of a plasmid expressing the FLAG-tagged human RIG-I (FLAG-hRIG-I) or myc-
tagged mouse RIG-I (myc-mRIG-I) either alone or with 100ng of the pCAGGS-PACT-
HA was included in the transfection reaction. Cell lysates were prepared at 48 hrs post-
transfection for Fluc and β-gal assays. Fluc activities were normalized to the β-gal values 
as previously described (231).  
ELISA assay: WT or NP RNase defective PICVs were used to infect WT, PACT KO or 
RIG-I KO MEF cells at MOI=1 or 0.1. Twenty-four hours post infection, the levels of 
IFNβ  in the supernatants of the virus-infected cells were quantified using a mouse IFNβ 
enzyme-linked immunosorbent assay (ELISA) kit (LEGEND MAX™ Mouse IFN-β 
ELISA Kit with Pre-coated Plates) following the manufacturer’s instructions. 
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qRT-PCR assay: WT or NP RNase-defective PICVs were used to infect WT, PACT KO 
or RIG-I KO MEF cells at MOI=5. Total cellular RNAs were extracted using the TRI 
reagent (Sigma) according to the manufacturer’s instructions. The extracted RNAs were 
treated with DNase (Promega) to eliminate genomic DNA contamination and re-extracted 
with Acid-Phenol: Chloroform (Ambion) according to the manufacturer’s instructions. 
Single-stranded cDNAs were generated using an oligo(dT) primer and MMLV reverse 
transcriptase (Promega) following the manufacturer’s protocol. Quantitative PCR was 
conducted with specific primers designed to detect mouse IFNβ, NFκB, ISG56 and the 
housekeeping glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene by using iQ™ 
SYBR® Green Supermix (Bio-Rad) on a Bio-Rad CFX quantitative PCR machine. The 
IFNβ and NFκB mRNA levels were quantified at 16 hrs postinfection, whereas the 
ISG56 mRNA levels were measured at 4 h post infection. The primer sequences were 
listed in Table 2. The PCR mixtures were incubated at 95°C for 3 min, followed by 40 
cycles of amplification at 95°C for 10 s and 55°C for 30 s. The RNA level of each gene 
from virus-infected cells was first normalized to that of GAPDH gene and then compared 
to that in mock-treated cells and shown as the fold changes in the graph. Results shown 
are the averages of one experiment done in triplicates. The experiment has been repeated 
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Table 2: Primers used in qRT-PCR 
 
This work has been published in the Journal of Virology (J Virol. 2018 Jun 13;92(13). 
pii: e00482-18. doi: 10.1128/JVI.00482-18) 
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Chapter V 
Discussion and Future Directions 
With globalization, human arenavirus-infected cases have been found all over the world 
by travelers to and from the endemic areas, which also increases the risk of disease 
outbreaks. The lack of specific FDA-approved arenavirus vaccines and the limitation of 
treatments highlight arenavirus infection as a significant public health threat. Therefore, 
understanding the basic biology of arenavirus life cycle and host immune response to 
arenavirus infection will undoubtedly aid the development of the much-needed vaccines 
and therapies against these deadly viral pathogens. My studies have filled in the 
knowledge gap by characterizing the functional mechanisms of viral GPC and NP 
proteins in arenavirus biology and pathogenesis, and are expected to guide the future 
development of novel antivirals and vaccines.  
My studies have revealed residues within SSP and GP2 CTP regions that are critical for 
GPC-mediated membrane fusion and viral replication. It has been shown that SSP and 
GP2 CTD play important roles in GPC processing and membrane-membrane fusion 
activity (167, 184, 244), but these functions have not been tested in authentic arenavirus 
infection. Using the PICV reverse genetics system, I have characterized the biological 
roles of conserved residues of SSP in vitro and in vivo and GP2 CTD in vitro. Some 
conserved residues (K33, F49 and C57 of SSP and H469, H471, C477, H481, C489, 
C491, and W503 of GP2 CTD) are essential for arenaviral life cycle and play important 
roles in regulating membrane-membrane fusion activity. These conserved critical 
residues could be targeted for developing anti-viral agent. Screening of small molecules 
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to inhibit GPC-mediated virus entry and membrane-membrane fusion has been reported 
(166, 245-248). Specific compound that targets K33 has been found to suppress GPC 
mediated membrane-membrane fusion activity (245). According to my SSP and GP2 
CTD study, screening for specific small molecules targeting F49, C57 and other 
conserved residues of GP2 are also promising. We also have shown the G2A and N20A 
mutants are attenuated in guinea pig models, suggesting that G2 and N20 could be used 
to attenuate arenavirus in the development of arenaviral vaccines. Many questions still 
remain to be addressed on the molecular mechanism of GPC-mediated membrane fusion 
and virus entry. In particular, the crystal structure of entire GPC is not available, we do 
not know the exact position of these conserved residues in either pre- or post-fusion form, 
which limits our understanding of the detailed mechanism of membrane fusion and the 
roles of these conserved residues play in GPC function. 
My arenaviral NP study has demonstrated the important roles of arenaviral NPs in 
suppressing RIG-I/PACT induced IFNβ production by its 3’-5’ exoribonuclease (RNase) 
activity. As such, screening for compounds that can inhibit the NP RNase activity (as 
described in the Introduction chapter (Chapter 1) and/or its role in mediating immune 
suppression in the PACT-RIG-I innate immune pathway as described in Chapter 4) 
warrants additional studies, especially when structural details of arenavirus NPs have 
been well studied (126, 228-230, 233, 249, 250). In particular, the RNase domain located 
at the C-terminal region of NP, which belongs to the DEDD superfamily (126, 228-230, 
233, 250) seems like a very good target for drug screening. In addition, the NP RNase 
activity can also be exploited for arenaviral vaccine development. Several studies have 
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shown that the NP RNase defective arenaviruses are attenuated in human primary cells 
and guinea pig models (129, 231). These results not only showed the essential roles NP 
played in the inhibition of innate immune response in authentic arenavirus infections but 
also indicated the value of this protein for developing arenaviral vaccines, i.e., by 
crippling NP ability to suppress immunity in order to enhance host recognition and 
response immunologically to the vaccines. 
My study also reveals novel mechanistic insights into the host innate immunity and virus-
mediated immune evasion. However, many questions remain to be addressed.  
(1) In Chapter 4, we showed that arenaviral NP can suppress the PACT-mediated 
enhancement of RIG-I function to produce type I interferon (e.g., IFNβ) in response to 
virus infection. In our study, we have shown that both RIG-I and PACT play important 
roles in restricting arenavirus replication in primary mouse fibroblasts. However, it is 
known that macrophages and dendritic cells (DCs) are the primary target cells for 
arenavirus infections. It is therefore important in future studies to investigate the roles of 
RIG-I, PACT, and NP in macrophages and DCs in the setting of arenavirus infection.  
(2) In this study, we also provided evidence to suggest that self RNAs could be targeted 
by arenaviral NPs as it is required for PACT function to enhance RIG-I activity to induce 
IFNβ production. A recent study has shown that self RNA such as cellular 5S rRNA 
pseudogene transcripts can activate RIG-I and induce IFNβ production (251). It is 
therefore important to characterize these self RNA species in future studies because they 
play important roles in the RLR pathway, especially their potential roles in the virus-
infected cells. 
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(3) LASV is an important human pathogen that causes human viral hemorrhagic fever. 
Characterization of the roles of PACT, RIG-I and NP in human cells is much more 
relevant in order to understand the mechanism of LASV-caused human disease. 
CRISPR/CAS9 system is a powerful tool to knock out genes from cells. We can generate 
PACT or RIG-I KO human cells such as 293 and A549 cells, and investigate the roles of 
PACT and RIG-I in LASV infection condition in the BSL4 lab. Since the LASV reverse 
genetic system is available, both WT and NP RNase defective LASV can be tested in 
these PACT or RIG-I KO human cells. The viral kinetics and immune response data from 
these experiments will help us to further understand the roles of PACT and RIG-I in 
LASV infection. 
(4) Animal model is the most important tool to investigate the pathology of the disease. 
The roles of NP, RIG-I and PACT has not been investigated in animal models in my 
study. To further address the roles of NP, RIG-I and PACT, PICV/LASV (WT and/or NP 
RNase defective virus) should be tested in animal models. Mouse models are convenient 
and cost-effective, however, normal mouse model is not a perfect animal model for 
arenaviral hemorrhagic fever, since normal mouse does not develop hemorrhagic fever 
symptoms. But recent studies have shown that some immunodeficient mice, such as IFN 
receptor KO and STAT KO mouse can be infected with LASV and JUNV and develop 
some symptoms that mimic LASV and JUNV caused human diseases. The IFN signaling 
pathway is severely impaired in these KO mice, which suggested the important roles of 
type I IFN in arenavirus infection mouse models. Our data has already shown that RIG-I 
and PACT play important roles in IFN production in arenavirus infected cells. PACT KO 
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and RIG-I KO mice are also available (252). Therefore, it is possible to use them as new 
mouse models for arenavirus infection studies, and the data obtained from these animal 
experiments will provide important insight into the mechanism of RIG-I, PACT in 
arenavirus infection. 
Taken together, my studies have characterized biological roles of arenaviral conserved 
residues of SSP and GP2 CTD, and a novel immunosuppression mechanism of NP. My 
studies not only provided potential targets for anti-viral agent/vaccine development but 
also gain insight into the immunosuppression of arenaviral NPs. My studies might help in 
improving our knowledge of arenaviruses infections and develop new treatment to 
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